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Abstract: Corneal structure is highly organized and unified in architecture with structural 
and functional integration which mediates transparency and vision. Disease and injury are 
the second most common cause of blindness affecting over 10 million people worldwide. 
Ninety percent of blindness is permanent due to scarring and vascularization. Scarring 
caused via fibrotic cellular responses, heals the tissue, but fails to restore transparency. 
Controlling keratocyte activation and differentiation are key for the inhibition and 
prevention of fibrosis. Ophthalmic surgery techniques are continually developing to 
preserve and restore vision but corneal regression and scarring are often detrimental side 
effects and long term continuous follow up studies are lacking or discouraging. 
Appropriate corneal models may lead to a reduced need for corneal transplantation as 
presently there are insufficient numbers or suitable tissue to meet demand. Synthetic 
optical materials are under development for keratoprothesis although clinical use is limited 
due to implantation complications and high rejection rates. Tissue engineered corneas offer 
an alternative which more closely mimic the morphological, physiological and 
biomechanical properties of native corneas. However, replication of the native collagen 
fiber organization and retaining the phenotype of stromal cells which prevent scar-like 
tissue formation remains a challenge. Careful manipulation of culture environments are 
under investigation to determine a suitable environment that simulates native ECM 
organization and stimulates keratocyte migration and generation.  
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1. The Importance and Correlation of Transparency and Scar Tissue 
Vision is reliant upon the discrete organization, structure and functional integration [1] of the 
corneal stroma and its components. Changes in corneal shape and structure that disrupt the complex 
organization cause scarring and opacities and are often the result of the majority of corneal diseases 
and injury [2,3]. Often corneal blindness is the result of corneal scarring and vascularization which if 
severe is permanent. The characteristics of scar tissue is an abnormal alignment of the collagen fibrils, 
which is directly associated with transparency of the tissue. The impact of scar tissue formation in 
corneal tissue is significantly greater than in other tissue types as it has direct impacts on vision. 
Understanding the in vivo mechanisms whereby the cornea is able to regenerate rather than repair is 
fundamental to clinical approaches as it often determines the difference between a functioning 
transparent cornea and an opaque scarred tissue.  
The cornea comprises one-sixth of the total ocular globe [1] (Figure 1) with a structure described as 
“the epitome of efficiently unified structure and function” [4] due to its complexity and extracellular 
organization. The avascular [5,6], sparsely populated, viscoeleastic [7,8], multilaminar structure [9] 
forms a barrier to protect the intraocular contents, is transparent to visible light and forms an almost 
perfect optical boundary to refract light onto the retina [9], providing two-thirds of the optical power of 
the eye [10].  
Figure 1. Basic anatomy of the human eye and location of the cornea. 
 
The corneal tissue consists of five distinct layers: Epithelial; Bowman’s; Stromal; Descemets; and 
Endothelial layers with the three cellular functional layers being the epithelium, stroma and the 
endothelium (Figure 2). A healthy epithelium has 5–7 cellular layers with 3 distinct highly 
differentiated and self-renewing cell types; the strata germinatum; daughter/wing cells; and squamous 
cells [11]. The epithelium’s main role is to protect the stroma from invasion by restricting foreign 
material entering the eye. The bowman’s layer is a transparent sheet of tissue residing just below the 
basement membrane of the epithelium. It is less complex in comparison to the other layers with 
randomly arranged collagen fibers [12]. It scars when damaged, resulting in vision loss if the scars are 
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large and centrally located [13]. The stromal layer occupies approximately 90% of the total thickness 
of the cornea and has the most organized extracellular (ECM) in the body [13]. The stroma is 
responsible for the overall strength and shape of the cornea [3]. Disruption to the stromal layer by 
disease or injury is often the cause of permanent blindness. The descemets membrane is a thin but 
strong barrier against infection and injury that aids in maintaining corneal curvature [8,14]. It is 
derived from secretions from endothelial cells [8,15] and is able to regenerate after infection. The 
endothelium is the very thin, innermost layer of the cornea. It is made up of closely interdigitated cells 
arranged in a mosaic pattern of mostly hexagonal shapes [11]. It is essential for keeping the cornea 
clear as it pumps excess fluid out of the stroma. This prevents stromal swelling, hazing and ultimately 
the occurrence of an opaque stromal layer. Endothelial cell loss results in enlargement and spread of 
neighbouring cells to cover the defective area [11]. Therefore, damage to the endothelial cells results in 
permanent destruction which leads to corneal edema (swelling) and blindness.  
Figure 2. (a) DAPI stained cross section of the cornea detailing the 3 distinct cellular 
layers of the cornea, E, Alicia J. El Haj pithelium, Stroma and Endothelium; (b) schematic 
representation of the corneal layers with additional Bowman’s layer and Descemet’s 
membrane detailed. 
 
(a) (b) 
Corneal transparency is heavily dependent upon the highly complex levels of organization and 
regular spatial order of the thin collagen fibrils within the stromal layer [3,16,17]. The collagen fibrils 
are approximately 25–35 nm [16,18] in diameter and are closely arranged [19] parallel to each other in 
200–250 nm thick layers (or lamellae) [18] (Figure 3). The collagen fibrils themselves are weak light 
scatterers of light as their diameters are less than the wavelength of light with a refractive index close 
to that of the corneal ground substances [19]. Fibril packing is denser in the anterior two-thirds and 
axial cornea, in comparison to the peripheral cornea [20]. The lamellae are a hydrated matrix rich in 
proteoglycans, glycoproteins, salts and keratocytes [21]. Keratocytes that reside between the lamellae 
100 µm 
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are responsible for the secretion of these components [22]. Within the central cornea there are 
approximately 200–400 lamellae [17,18,21] that span from limbus to limbus [23]. Lamellae 
organization and distribution is believed to control the corneal shape and curvature.  
Figure 3. A schematic representation of (a) a cross sectional view; (b) a top view of the 
microstructural arrangement of the collagen fibrils: the collagen fibrils within the stromal 
layer are arranged parallel to each other in regularly spaced lamellae sheets. 
 
(a) (b) 
The collagen fibrils are almost monomized in diameter (same shape and size) [1] across the 
majority of the cornea [16], but raises abruptly from approximately 4 nm from the centre to nearly 
50 nm at the limbus [16]. Fibril diameter [16] and local interfibrillar spacing [1] does not alter with 
corneal depth, but has been shown to increase slightly with age [24]. The proteoglycans are thought to 
be responsible for the spatial distribution and organization of the collagen fibrils [3,24]. Electron 
microscopy and X-ray diffraction studies [25] indicate that the fibrils in adjacent stromal lamellae are 
predominantly orthogonal in arrangement [26]. It is the nanoscale organization of the stromal layer that 
is responsible for the corneas strength, clarity and its ability to refract light. It is also the principle 
reason why tissue engineered corneas have thus far failed to reach the clinic [1]. 
2. Diseases Linking to Scar Tissue Formation in the Cornea 
Corneal diseases are vast and diverse with epidemiologies encompassing an array of infectious and 
inflammatory diseases. Corneal diseases are the second most common cause of vision loss and 
irreversible blindness to cataracts [27,28] globally affecting over 10 million patients [27,29] usually 
manifesting as a badly damaged ocular surface [28]. 180 million people worldwide are acutely visually 
disabled (although not classed as blind) discounting the further hundreds of millions affected by 
monocular visual loss [30]. The occurrence of corneal blindness is variable from country to country 
and between populations [30]. The prevalence is also accustomed to the availability and standards of 
eye care. For example, in some parts of Africa and Asia, corneal scarring is 20 times more likely than 
in industrialized countries.  
A great deal of research is focused upon diseases of the cornea as they are often responsible for 
changes in shape and thickness of the cornea [2] which may lead to permanent opacities which 
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ultimately lower visual acuity [31]. Visual acuity is measured on a Snellen scale. The first number of 
the scale is the distance (in meters) away from the chart required to read it. This is usually 6 (i.e., 
6 meters). As many rooms don’t have 6 meters available, a half-sized chart is used with the acuity 
expressed a ratio within a numerator of 6. The second line corresponds to the number of lines on the 
chart. 60 corresponds to the biggest letters, on the top line. The bottom line (i.e., smallest letters) 
corresponds to the number 6. Standard vision is defined as 6/6. The World Health Organization 
(WHO) definition of blindness is a visual acuity of 3/60 or less [30].  
Historically, corneal blindness has been caused by disease including, although not exclusive to, 
trachoma, onchocerciasis, leprosy, opthalmia neonatotrum, xerophthalmia and opthalmia neonatorum. 
However, blindness due to ocular trauma, corneal ulceration and complications from using traditional 
medicines are becoming more commonplace as they often include dried plant materials crushed and 
dissolved into non-sterile aqueous medium, and may also include urine and saliva from animal or 
human sources, which present an excellent mechanism for pathogenic organisms to enter and spread 
into eyes that are already injured or infected [30]. A summary of corneal diseases specifically linked to 
scar tissue formation is provided in Table 1.  
Table 1. Corneal diseases linked to scar tissue formation; their epidemiology, causes 
and treatment. 
Disease Epidemiology Causes Treatment Further information 
Fuchs 
dystrophy 
Deterioration of 
endothelial cells. 
Loss in efficiency of 
pumping water from 
stroma. 
Swelling and 
distortion of cornea. 
Changes in the 
cornea’s curvature. 
Hazing. 
Tiny blisters on 
corneal surface. 
Glare and light 
sensitivity. 
Usually affects both 
eyes. 
Thought to be 
inherited, autosomal 
dominant trait [32]. 
Gene mutation 
strongly suspected. 
Salt solutions such as 
sodium chloride drops or 
ointment are often 
prescribed to draw fluid 
from the cornea and 
reduce swelling. 
Contact lenses. 
Hair dryer to dry out 
corneal blisters. 
Short-term success with 
transplantation, but long-
term survival is a 
problem. 
Cannot be cured. 
Ocular 
trauma and 
ulceration 
Unilateral vision loss. 
Ulceration. 
Corneal perforation 
Endophthalmitis. 
Phthisis. 
Blindness. 
Hyphaemas [33]. 
Ruptured globes. 
 
Mechanical trauma, 
debris entering the eye, 
chemical and thermal 
burns. 
Workplace activities, 
such as mining 
injuries, agriculture 
and warfare. 
Road accidents [33]. 
Domestic accidents [33]. 
Corneal transplant. 
Antibiotic and antifungal 
treatments although 
visual outcome usually 
poor [30]. 
Ocular traumas are 
becoming more prevalent 
causes of scarring and 
blindness. 
Worldwide, half a million 
people are blind as the 
result of trauma [30,33]. 
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Table 1. Cont. 
Disease Epidemiology Causes Treatment Further information 
Opthalmia 
Neonatorum 
(conjunctivitis 
of the 
newborn) 
Bilateral scarring. 
Blindness. 
Affects both eyes. 
Infection caused by 
Neisseria 
gonorrhoeae. 
Herpes simplex virus 
(HSV) can also cause 
childhood corneal 
blindness by causing 
opthalmia and 
xerophthalmia, 
although such 
infections are 
infrequent in infants. 
Saline washes. 
Antibacterial eye 
ointments. 
Treatments with 
tetracyanite/erythromyci
n/silver nitrate 
ointments. 
Blindness risk is reduced 
when opthalmia 
neonatorum is caused by 
less virulent pathogens 
such as Chlamydia 
trachomatis [30]. 
Stevens-
Johnson 
Syndrome 
(SJS) also 
known as 
Erytheme 
multiform 
Subepithelial bullae. 
Scarring. 
Keratinocyte 
apoptosis of the 
surrounding skin 
and epidermal 
necrolysis. 
Erosion of mucous 
membranes [34]. 
Scarring. 
Bilateral blindness 
[35]. 
Drugs including 
sulphonamides, 
anticonvulsants, 
salicytes, NSAIDs, 
penicillin [34]. 
Infection, such as 
HSV. 
Streptociocci, 
adenovirus and 
microplasma [35]. 
Withdrawal of all 
potential causative drugs 
[35]. 
Intravenous fluid 
replacement. 
Immunosupressive 
therapy. 
Corneal stem cell 
transplant. 
Corneal transplant. 
<100 drugs associated 
with SJS [34]. 
Most severe cases referred 
to as toxic epidermal 
necrolysis (TEN) 
Transplanted tissue often 
rejected. 
Xerophthalmia 
(dry eye 
syndrome) 
Night blindness. 
Xerosis. 
Corneal perforation. 
Scarring. 
Irreversible 
blindness [36]. 
70% of cases are due 
to a vitamin A 
deficiency [30,36]. 
Artificial tears. 
Increase humidity of 
surroundings. 
Vitamin A 
supplementation. 
Xerophthalmia patients 
are predominantly infants 
or young children, with a 
peak age of approximately 
2.5 years [36]. 
All but disappeared in 
Western Europe [36]. 
Trachoma 
Vascularization. 
Ocular surface 
problems Entropion. 
Trichiasis. 
Bacterial infection 
trachoma caused by 
Chlamydia 
trachomatis [30]. 
Infection can be 
transmitted from eye 
to eye via 
contaminated fingers, 
clothes, make-up and 
flies. 
Corneal transplant. 
The disease is 
preventable via antibiotic 
treatment with 
azithromycin [37]; 
however more antibiotic 
treatment is still required 
to prevent further 
progression of the 
infection to corneal 
blindness in previously 
infected individuals [30]. 
World’s leading cause of 
ocular morbidity and 
blindness [30]. 
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Table 1. Cont. 
Disease Epidemiology Causes Treatment Further information 
Onchocerciasis 
(river blindness) 
Destructive 
chorioretinitis. 
Blinding keatitis 
Acute corneal 
scarring. 
Vascularization. 
Caused by a parasite 
Onchocerca volvulus 
[30]. 
Collagenase secretion, 
caused by the influx of 
inflammatory cells is 
believed to be 
responsible for the 
rapid destruction of the 
xerophthalmic cornea 
[36]. 
Invermectin kills the 
microfilaria (larval form) 
and sterilizes the adult 
worm to prevent spread 
in infected individuals. 
 
Incidences of 
onchoceriasis have 
decreased since the 
introduction of 
invermectin in the 1980s. 
Leprosy 
Blindness. 
Chronic uveitis. 
Cataract 
formation. 
Exposure keratitis. 
Reoccurring 
corneal ulcers. 
Corneal scarring. 
Vascularization. 
Mycobacterium laprae 
usually affects the 
anterior segment of the 
eye. 
Multi drug therapy using 
dapsone, rifampicin and 
clofazamine. 
Corneal complications 
caused by leprosy are a 
significant cause of 
corneal blindness globally 
affecting 250,000 people, 
predominantly in Africa 
and Southern India. 
The majority of corneal diseases are the result of some form of disruption to the fibril arrangement 
in the stromal layer [3] and are a major cause of blindness worldwide. In areas of Africa in particular, 
over 90% of blindness is a result of corneal pathology, and the corneal scarring and vascularization is 
so severe that blindness is permanent. Unfortunately, many of the current treatments are not cost 
effective and can only alleviate or treat secondary symptoms of the disease and fail to cure the 
underlying cause. Prevention, in the cases of most diseases, would be more cost effective and successful 
in eliminating corneal blindness. However, more knowledge is still required to help us to understand the 
underpinning mechanisms that lead to permanent scarring in diseased and injured corneas.  
3. Mechanisms of Wound Healing in the Cornea 
The ability of the cornea to remain transparent can become compromised when the cornea is 
exposed to trauma, infection, ulceration or chronic inflammation [38]. Much of the knowledge 
concerning corneal wound healing is derived from animal studies [39]. These are very valuable but 
anatomical differences such as the lack of a bowman’s layer in rabbit eyes mean that some caution 
should be exercised when extrapolating animal models to human clinical findings [39]. Corneal wound 
healing and the mechanisms involved are complex and include a cascade of cytokine mediated 
interactions between epithelial, stromal and endothelial cells, corneal nerves, lacrimal glands, tear film 
and cells of the immune system [40,41]. Activation of these mechanisms attracts immune cells which 
are responsible for eliminating debris and microbes that penetrate into the stroma [40]. However, it 
should be noted that most of the mechanisms that occur during wound healing are similar to those that 
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occur during normal homeostasis [40]. In general, corneal wound repair occurs in 3 overlapping phases 
including re-epithlization and migration; cell proliferation and synthesis; and the remodeling of the 
underlying ECM [40,42] with many growth factors and cytokines stimulating one or more of these 
phases during repair [42]. Cell-cell cross-talk is vital to wound healing and occurs in a reciprocal 
manner, the signaling is not mutually exclusive and the action of one may depend or mediate the 
expression of the other [40]. The interaction of the cytokines leading to a network-like action is pivotal 
to the final outcome of wound healing [40]. However, the wound healing response and resulting tissue 
changes are dependent upon the size, depth [39,40] and inciting injury, with the severity of the 
response affecting the overall outcome [41]. Tear quality and integrity is also of importance as tear 
deficiencies can compromise the wound healing process [39]. The principal purpose of any wound 
healing response is to regain anatomical and functional capacity in the fastest and most perfect way. 
Elsewhere in the body, wound healing often ends in scar formation and vascularisation, where as one 
of the most vital aspects of corneal wound healing is the minimization of such results which would 
otherwise have serious visual consequences [39]. Healing of corneal tissue is slower than other 
connective tissues; possibly due to its avascularity [39].  
The remodeling process of the injured stroma is vital to the resulting architecture of the tissue 
deposited following injury [41]. The synthesis, breakdown and cross-linking of collagen are all 
involved in the strengthening and stabilization of the wound and such processes can last for months to 
years. The remodeling process is able to alter the architecture of the initial repaired tissue so that it 
reverts to that of a non-injured state. Understanding these mechanisms and the factors involved may 
aid in the development of therapeutic agents which can speed up this process. 
In mammals when a tissue is damaged a fibrotic response is usually activated which heals the 
tissue, but fails to restore full function [43]. However, in some instances such as during fetal wounding 
or some corneal wounding healing takes on a regenerative capacity whereby full function is restored. 
Corneal reaction to injury can be attributed to the architecture of the initial wound [44]. A theory of 
“activation” has been suggested by Fini et al. [43] where upon cells that undergo fibroblastic 
differentiation in response to injury will repair tissue; whereas cells that are able to proliferate in 
response to injury without activation will regenerate the damaged tissue. The subtle difference 
between the two could be the difference between an opaque tissue and a functioning transparent tissue. 
One of the most demanding challenges of corneal biology is to assist tissue repair via regeneration 
rather than fibrosis [45]. The cornea is a useful model for studying wound response and cell phenotype 
due to the unique homogenicity of the cell types that reside in the corneal stroma and remarkably 
organized tissue architecture that if disrupted has immediate and obvious effects [43,46].  
3.1. Regeneration 
There are a number of stem niches in ocular tissue that are vital to maintenance, repair and 
regeneration [1]; these include limbal stem cells (LSCs). LSCs are able to self-renew and generate 
daughter cells that can continue to differentiate until they are eventually shed [1]. In vivo the 
epithelium is regularly renewed from a population of relatively undifferentiated cells found in the basal 
layer of the corneal limbus. The limbus is the narrow ring of tissue located between the cornea and 
conjunctiva that ends anteriorly at the Bowman’s membrane. It supplies physical protection and 
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nutrition to the stem cells. LSCs are normally slow-cycling, self-renewing cells that produce transient 
amplifying cells (TACs). TACs are capable of multiple rounds of division that does not usually occur 
during normal homeostasis [40]. Proliferation takes place which generates more TACs dependent upon 
the necessity, i.e., more proliferation occurs during regeneration (it can increase up to nine-fold) 
following a corneal wound. Usually, the average cycle time of a TAC is 60 h, but this can be shortened 
to 24 h upon stimulation [40]. The upregulation of stem cells and the increased proliferative capacity 
of TACs amplifies each cell division and reduces the need for stem cell proliferation whilst 
minimalizing the chance of introducing replicative DNA errors into the stem cell population which 
effectively provides a large number of terminally differentiated post mitotic cells [40] that move 
towards the centre of the cornea and upward from the basal corneal epithelial cell layer [1]. The final 
differentiated cells are eventually shed. The migratory epithelial cells are thought to move across the 
surface of the wound surface via a cyclical process involving philipodia and lamellipodia [39] that 
form temporary focal adhesions, whilst intracellular contractile mechanisms draw the cell forward. The 
focal adhesions are then cleaved enabling the process to be repeated in a cyclic fashion [39]. Epithelial 
repair is critical to the healing process [44]. Re-epithelialzation does not occur one layer at a time; 
there is a gradient of basal and suprabasal cells from opposite directions that meet in the centre [40]. 
The adjoining stromal layer is important to stem cell density, although the exact mechanism 
controlling this remains elusive. Complex intercommunications between the stem cells and their 
surrounding microenvironment are pivotal to this role [1]. The surrounding environment of LSCs and 
TACs differ and are principal to deciding cell fate in each region. Stromal regeneration, as opposed to 
repair, is dependent upon highly coordinated cellular interactions between epithelial and keratocyte 
cells [47]. Keratocytes originate from a population of neural crest cells. It has been postulated that 
some of the regenerative properties exhibited by these cells following corneal wounding could be 
attributed to their stem-like properties retained from their cell of origin [10]. An example of keratocyte 
regeneration is the healing of epithelial debridement wounds. In these cases, where the epithelium has 
been scraped away exposing the basement membrane, the keratocytes beneath the membrane undergo 
apoptosis. Mitosis of the adjacent cells occurs, which replace the cells, and no additional response 
occurs [10]. The initial cell apoptosis is thought to occur to prevent an inflammatory response 
occurring which may affect corneal transparency, which effectively protects the cornea from  
self-harm. However, the area and extent of cell death is variable and dependent upon the severity of the 
original injury and the species of the animal [10]. 
Preservation of the basement membrane has been attributed to the difference between regeneration 
and scarring [46,48]. The basement membrane is important in the regulation of epithelial-stromal 
interactions [46]. The presence of an intact basement membrane during wound healing is effective in 
hindering epithelial pro-fibrotic cytokines and growth factors [46], preventing their production whilst 
promoting re-epithilization. Thus the basement membrane provides effective anti-fibrotic protection to 
both the epithelium and stroma. 
Reconstitution of transparency following injury is dependent upon the subtle mediation of 
biosynthetic activities of post-injury fibroblasts and matrix degradation attributed to proteolytic 
enzymes (enzymes that catalyze the splitting of proteins into smaller peptide fractions) [46]. It has also 
been suggested that regenerative healing is dependent upon the execution of 3 distinct phases:  
(i) fibroblast migration and secretion of proteases, ECM and growth factors; (ii) fibroblast 
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differentiation into nonmotile, contractile myofibroblasts that secrete ECM proteins and remodel the 
ECM; (iii) wound closure and myofibroblast apoptosis [49]. It is the persistence of myofibroblasts that 
cause overproduction of ECM and excessive contraction [49] that lead to scarring and opacities.  
Investigations into experimentally injured adult rabbit corneas [50] have suggested that corneal 
regeneration recapitulates developmental stromal events regarding proteoglycan expression resembling 
that of early development. Corneal development has fascinated researchers for over 100 years [51]. It 
involves a precisely controlled sequence of events whereby the embryonic cornea undergoes key 
structural changes vital to its overall form and function. Embryonic chicks are predominantly used in 
the study of corneal development [51], however gene targeted deficient mice and zebra fish are also 
important model organisms in studying vertebrate corneal development [50].  
Corneal embryogenesis, like regeneration, is dominated by important changes in structure and 
composition of the ECM. The collagen fibrils in the avian stroma are deposited in a two stage-process 
to form the corneal matrix. Although this two-stage process is not so obvious in non-avian corneas, 
differences in the outer and inner corneal development are still apparent in human corneal 
development. The corneal epithelium inhabits a large section of the corneal thickness (69%) during 
early development, consisting of undifferentiated multi-stratified cells lacking in the usual layered 
organization [50]. Initially, the epithelial cells secrete a primary matrix which is thought to act as a 
template for the following biosynthesis of the secondary stroma by the neural crest cells which later 
become keratocytes [51]. The epithelium increases in thickness (80% overall thickness) as it becomes 
more developed and organized. The cells arrange into 3–4 distinct layers [50] which eventually flatten 
out thus reducing epithelium thickness. The primary evidence of corneal ECM is a very thin layer [50] 
of fine collagen fibrils, known as the “primary stroma” which is a product of ectodermal cells (one of 
the 3 primary cell germ layers) [51]. A two-wave mesenchymal cell migration occurs from the 
periphery into the primary stroma. Most of the early migrating cells will form the endothelium; the 
secondary cells will become stromal fibroblasts. The invading cells cause stromal swelling and an 
increase in thickness. The corresponding widespread invasion of fibrotic mesenchymal cells, destined 
to become keratocytes, begin to populate the stroma and synthesize much of the secondary stroma by 
depositing collagen fibrils as coarse lamellae [51]. It is thought that the migrating cells use the primary 
stroma as a template; however the exact mechanism is unclear. The stroma increases in thickness 
before undergoing a marked compaction process as water is lost, concentrating the matrix components 
and at the same time increasing transparency. The cornea is thicker in the middle stroma compared to 
the anterior stroma [50]. Proteoglycans are pivotal to corneal morphogenesis; they interact with 
collagen and control the size, diameter and arrangement of the fibrils whilst helping to determine the 
hydrophobicity and swelling properties of the matrix [51]. They also aid in cell migration and cell 
differentiation. Initially there are only a small number of proteoglycans which aggregate below the 
epithelium and above the endothelium, significantly increasing in size and number as the  
cornea develops [50].  
During early corneal development the collagen fibrils are already in an orthogonal order. The 
lamellae are progressively deposited and rotate in sequence beneath the epithelium. The direction and 
rotation of the lamellae is a self-assembly process whereby the matrix itself dictates the evolving 
architecture [51]. Influencing orientation factors are largely unknown, however may be due to 
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biomechanical stresses in the stroma caused by intraocular pressure and direct interactions between 
matrix components [51].  
Fibrillogenesis occurs within small surface recesses of keratocytes with small bundles between  
5 and 12 fibrils. The smaller bundles combine into larger bundles, before eventually becoming 
lamellae [51]. The number and orientation of the lamellae become more established with increasing 
development and successive synthesis and addition of more collagen and ECM components. 
Dehydration of the cornea becomes apparent as a thinning of the secondary stroma followed by structural 
reorganization of cells and ECM [51]. The endothelium contributes greatly to the dehydration process 
although the exact role is not known. The endothelium itself is initially very thick (23% corneal 
thickness), but decreases in thickness over time [50]. Small stromal proteoglycans, such as keratocan 
sulfate may mediate the fibrillar organization on a localized level via interactions with collagen and 
each other, rather than having a global matrix compaction effect [51].  
3.2. Scar Formation 
Although the cornea is exceptionally resistant to immune response and stimuli in comparison to 
other tissues in the body [43], scaring of the cornea can occur for many reasons. Debris and/or 
chemicals entering the eye, infection, inflammation and diseases of the cornea can all lead to 
permanent scarring. Scar tissue formation often changes the optical properties of the cornea, thus 
altering sight. Injuries to the cornea manifest as changes in cell phenotype particularly in the stromal 
layer. The disruption of the Bowman’s layer and Descemets’s membrane are also both key steps in 
initiating tissue remodeling [46]. A fibrotic response usually involves rapid contraction and closing of 
the wound space by activated keratocytes (fibroblasts) followed by scarring. However, keratocyte 
activity does not manifest until the corneal surface has been fully re-epithelialized [39]. In the case of 
fibrotic response in corneal wound healing opaque scar tissue will ultimately interfere with vision and 
the strength of the corneal scar tissue will never match that of uninjured tissue [39]. The primary stages 
of wound healing involve removal of the injured tissue, followed by cell proliferation and migration to 
the wound site. Here repair and replacement occurs before the wound healing procedure has ended [52]. 
During scarring a change in collagen or proteoglycan structure alters the usually highly organized 
lattice structure, thus decreasing the optical properties of the cornea. Corneal scar tissue is hazier, lass 
elastic, with lower mechanical properties than a normal, healthy adult cornea [47]. The structural 
origin for the haziness of scars is debated between researchers. Increased cellularity of the scar [38], 
vacuolation (an increased number of vacuoles present), or light scattering occurring due to a modified 
collagen fibril arrangement are all plausible explanations. In electron microscope studies on scarring [47] 
new scars have been shown to contain vacuoles (vesicles found within the cytoplasm of cells) with 
collagen fibrils with a normal average diameter, but a larger range of diameters. Transparency can 
improve over time as the spacing between the fibrils nears normal, although vacuoles remain. Even 
after prolonged periods of healing (up to 18 months), original collagen structure and cross linking is 
not restored, thus scar remodeling is never perfect and remains incomplete, i.e., it never returns to its 
pre-injured state.  
Damage to the corneal endothelium has also been well documented, as endothelial integrity is 
pivotal to the maintenance of corneal transparency [39]. The endothelial cells are often disrupted 
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during corneal, trauma, disease and surgeries which leads to stromal dehydration and hazing [42]. 
Additionally, over hydration of the endothelium can also cause corneal opacity. This is due to the loss 
of the tight junctions and integrity of the epithelium during wounding, which consequently affects cell 
membrane permeability leaving the cornea more vulnerable to infections by microbes [40]. The 
invasion of microbes disrupts cytokine-mediated control of healing which decreases endothelial fluid 
transport, thus increasing stromal hydration [40]. As many as 80% of endothelial cells can be lost 
before decomposition occurs [39]. Endothelial cells in humans and primates have minimal or no 
capacity to proliferate and thus endothelial wound healing is dependent upon the enlargement and 
migration of the surrounding cells to cover the wound site [53]. Additionally, endothelial cells in vitro 
have limited proliferative capacity [42] and so the use of growth factors may have a key role in 
regulation and stimulation of the healing endothelial layer.  
In some contexts scar formation represents fetal corneal synthesis in that the fibrils secreted in the 
initial stages of a scar are comparable to the diameter of the parallel bundles of fibrils secreted during 
embryogenesis [47,54]. Additionally, activated keratocytes express fetal surface antigens for up to 
6 weeks following injury. However, differences are apparent with respect to the reduction in the ratio 
of interfibrillar type VI collagen to type I collagen in scar tissue compared to the developing cornea, 
and lack of the original organized template in fetal tissue. 
4. Effectors to Control the Outcome of Corneal Wound Healing 
4.1. Phenotype Differentiation in the Corneal Stroma 
Quiescent keratocytes inhibit the stromal layer in a healthy cornea in vivo [43,55–58]. When viewed 
in cross section they appear as sparsely populated flattened cells located between the collagen lamellae. 
However, when viewed en face they appear as broad cells that form an elaborate network [43] 
interconnected by long dendritic processes [10] (Figure 4b) joined by gap junctions [48]. Keratocytes 
are responsible for the synthesis of the stromal ECM which is vital to maintaining transparency. The 
main function of the keratocyte is to maintain the balance of stromal substances by synthesizing new 
collagens and proteoglycans, whilst secreting collagenase amongst other enzymes to degrade old 
stromal matrix [58]. Keratocytes contain highly expressed proteins known as crystallins, which 
contribute to the transparent nature of the cornea.  
During wound healing, an epithelial slide is initiated at the wound edge. This is independent of cell 
division and cell migration is achieved via a migration of slow cycling stem cells situated in the basal 
layer of the limbus [47]. The sliding cells release plasminogen activators (a precursor to plasmin) that 
cleave transient macromolecular focal contacts released as the epithelial cells migrate. The epithelial 
layer thins over protruding areas of the wound and thickens over the wound area, effectively producing 
an even, smooth corneal surface [47]. The epithelial cells co-ordinate with the keratocytes in the 
stromal layer below via cytokine release mechanisms, which aid and stimulate migration and 
proliferation. The cytokine release attracts inflammatory cells (such as macrophages and T-cells) into 
the stroma, resulting in an inflammatory response [45]. Keratocyte migration back into the original 
wound site only occurs once the wound surface has been re-epithialized.  
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Figure 4. F-actin stained fluorescent images showing differences in morphology of  
(a) a fusiform fibroblast compared to (b) a more dendritic shaped keratocyte.  
 
(a) (b) 
This inflammatory response initiates phenotypical changes to the keratocyte. Previous in vivo 
studies on rats [43], cats [59] and rabbits [43,60] have enabled the changes of a keratocyte into an 
activated repair fibroblast to be observed [43]. Keratocytes in close proximity to the wound edge 
undergo apoptosis and disappear within a few hours, leaving an acellular area. This activates the 
keratocytes flanking the acellular area within 6–24 hrs after the initial injury. Ultrastructural and 
biochemical studies demonstrate that keratocytes are markedly different from fibroblasts (Figure 4b) 
with regards to intracellular distribution of filamentous actin and form stress fibers characteristic of 
myofibroblast-like cells [61]. These changes allow usually quiescent cells to migrate to the injured area 
and proliferate. This process can last up to 7 days. Corneal fibroblasts are greater in size than 
keratocytes with a fusiform shape. They secrete higher levels of ECM proteins and enzymes [62,63] 
and so are able to reconstruct and repair the injured tissue. The differences in composition of ECM 
synthesized by corneal fibroblasts in comparison to keratocytes may account for the opacity of the 
resulting repair tissue [43], as the resulting scar tissue has a different composition compared to healthy 
tissue. Epithelial cells are gradually moved upwards and their remaining attachments are combined 
into the remaining scar. Keratocyte activity reverts to normal usually after 3 months [47], although 
hypercellularity (an abnormally large number of cells) can remain for years. 
During wound closure a subpopulation of corneal fibroblasts appears: the myofibroblast. 
Myofibroblasts are greater in size, less mobile and exert greater contractile forces on a tissue in 
comparison to fibroblasts [64]. Myofibroblasts are fundamental to wound contraction and 
scarring [49,65]. They are characterized by the presence of actin fibers, including α-smooth muscle 
actin (α-SMA) [59,64] which helps to convey contractile properties of the cell [43,59]. Optical 
transparency may return with time, but even after 6 months the cells in the scar are not normal 
keratocytes, although they may share many similar characteristics [43]. Corneal fibroblasts and 
myofibroblasts have been identified in vivo many weeks after the injury has occurred [8,66]. It is still 
not fully explained if the fibroblasts and myofibroblasts ever fully revert back to the uninjured 
50 µm 50 µm 
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keratocyte phenotype both morphologically and biochemically. It has been hypothesized [57] that 
corneal fibroblasts can partially return to the original keratocyte phenotype but some fibroblastic 
characteristics are retained [57,67]. It has been suggested that myofibroblastic differentiation is not 
activated by stromal injury alone and it is in fact a consequence of both stromal and epithelial  
injury [65]. The precise involvement of the corneal epithelium in corneal stromal wound healing is not 
known. However, deviations of its barrier function render it permeable to cytokines and growth factors 
from the tear film. These may then penetrate into the stromal layer, thus causing activation of the 
residing keratocytes [48].  
In summary, it is possible to induce keratocytes isolated from a natural cornea to differentiate 
into 3 (possibly more) different phenotypically different cell types; keratocytes, fibroblast and 
myofibroblasts [55]. 
4.2. Growth Factors 
In a healthy, uninjured cornea cell generation and loss, and the quantities of growth factors that 
stimulate and inhibit, are balanced. Injured cells generate cytokines- powerful peptide or glycoprotein 
regulatory factors that serve as autocrine or paracrine agents to control cell communication, migration, 
proliferation, protein synthesis [47] inflammation, differentiation and angiogenesis [52]. Cytokines 
regulate both epithelial and stromal wound healing responses [1]. The cytokines are thought to 
originate from the lacrimal gland, conjunctiva and conjunctival vessel that are secreted into the tear 
film during would healing with differing concentrations measured in accordance to different  
corneal pathologies [52].  
Wound healing is regulated by a vast assortment of growth factors, including but not exclusive to 
platelet derived growth factor (PDGF), epidermal growth factor (EGF), transforming growth factor 
beta (TGF-β), basic fibroblast growth factor (FGF, also known as bFGF and FGF-2), the interleukins 
(Il-1, Il-6, Il-8), tumor necrosis factor alpha (TNF-α) [47], insulin-like growth factor (IGF) [68], 
keratinocyte growth factor (KGF), hepatocyte growth factor (HGF) and secreted protein, acidic and rich 
in cystine (SPARC) [65]. In vivo all these growth factors differentiately co-ordinate keratocyte 
proliferation, cytoskeletal organization and ECM synthesis [68] via a complex cascade mechanisms [41]. 
Growth factors are able to act on corneal tissues through autocrine (self-acting, the growth factor acts 
upon the cell that produces it), paracrine (growth factor acts upon cells in the vicinity of the emitting 
cell) or juxtacrine (affecting both emitting cells and cells in the vicinity) fashions [69,70] and the 
presence of multiple growth factors have varying responses dependent upon their relative 
concentrations [70]. For example, KGF and HGF act via paracrine mechanisms where as TGF-β 
mediates as a paracrine system; PDGF can act via juxtacrine mechanisms [69]. The effects of growth 
factors on a cell type can vary dependent upon ECM environment [70]. The binding of growth factors 
to ECM leads to sequestration or controlled release that may regulate or enhance the growth factor 
effect [70]. Upon binding, integrin signaling, shape and cytskeletal tension which control cell cycle 
progression initiated by growth factors are changed [70]. Cells stimulated by growth factors cause 
them to produce or alter ECM and promote migration via enhanced integrin expression, affinity or 
cytoskeletal interactions [70]. 
J. Funct. Biomater. 2012, 3            
 
 
656
Epithelial cells secrete type I cytokines including TGF-β, Il-1, and PDGF [1]. TGF-β and PDGF in 
particular are powerful chemotactic agents and mitogens (stimulate mitosis) for fibroblasts and can 
initiate wound contraction [17,65]. TGF-β is arguably the most documented growth factor associated 
with corneal wound healing in literature and recent investigations into molecular therapy have been 
focused upon the inhibition of myofibroblast differentiation via the targeting of TGF-β isoforms [41]. 
The TGF family can be divided into two subfamilies, TGF-α and TGF-β [69]. TGF-α is similar to EGF 
in that it stimulates epithelial proliferation and has a common receptor; whereas TGF-β is very different 
and is secreted by almost all nucleated cells [69]. In vivo, the TGF-β superfamily are structurally 
related [71,72], mulitifunctional growth factors principally related to fibrosis, myofibroblastic 
differentiation [49,65,68,73,74], embryonic development, increased granulation [71] and contraction in 
many cell types; and loss of transparency specifically in corneal tissue. Three isoforms of TGF-β have 
been identified in mammals, TGF-β1, -β2 and TGF-β3 [40,41,69–71,73,75]. TGF-β1 and TGF-β2 have 
been localized in both the corneal epithelium and stroma and are both components of tear fluid [72]. 
mRNA of the TGF-β3 has been isolated from whole rat corneas in low levels, although its exact tissue 
location remains unclear and it has yet to be isolated and detected in non pathological corneas [72]. 
The receptors for TGF-β1 and TGF-β2 have been located in all three corneal cellular levels, being 
most prominent in the basal layer of the corneal epithelial cells [72]. The receptor for TGF-β3 has been 
located in the epithelium and endothelium in vivo, but is not present in native keratocytes [72]. 
TGF-β1 is the most commonly documented isoform that induces fibroblastic and myofibroblastic 
differentiation, although the TGF-β2 and TGF-β3 isoforms have been shown to elicit a similar 
transformation [73] with regards to stimulating cell stratification and matrix component production 
(such as collagen type I deposition) [71]. However, many studies have also demonstrated that despite 
the fact that the three isoforms share binding sites and are capable of activating the same effect of 
receptors; the overall effects are markedly different [71]. TGF-β2 has been established as the primary 
mediator of fibrosis and scarring as it is believed to play a role in the development of excessive ECM 
build up [73] and along with TGF-β1 increases fibrotic gene marker expression [71] such as α-SMA and 
collagen type III. Both TGF-β1 and -β2 are very potent growth factors that are capable of blocking 
epithelial, lymphocyte and hepatocyte cell proliferation promoted by KGF, EGF and HGF [69,70], 
whilst stimulating the proliferation of mesenchymal originating cells such as fibroblasts. Interestingly, 
the TGF-β3 isoform has been shown to act as an inhibitor of fibrosis and scar development [71], and 
has been shown to promote scar-free healing. TGF-β is auto-inductive for fibroblasts (secrete more and 
more) therefore an additional process is required to stop the stromal repair mechanism once the wound 
is closed [47].  
PDGF exists as a dimeric glycoprotein comprised of two A (AA) and two B (BB) chains, or a 
combination of the two (AB) [69]. PDGF can facilitate TGF-β myofibroblast differentiation via an 
autocrine feedback loop [68]. PDGF-BB stimulates keratocyte proliferation, upregulation of the 
secretion of normal stromal ECM and migration of both keratocytes and fibroblasts [68,76]. Thus 
PDGF-BB may regulate stromal migration and proliferation following injury without initiating the 
production of fibrotic tissue. PDGF-AB on the other hand has been shown to differentiate keratocytes 
to fibroblasts, evident via the development of stress fibers, local adhesions and contraction in 3D 
matrices [68]. Similarly, PDGF-BB is able to significantly increase the growth of endothelial cells in vivo 
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where as PDGF-AA does not [69]. However, neither TGF-β, Il-1, nor PDGF will exert their proliferation, 
chemotaxis or differentiation effects on stromal cells under normal homeostatic conditions [46]. 
Il-1 and soluble Fas ligand are cytokines released by epithelial cells in response to injury [77] and 
have been associated to the upregulation of HGF [41] and KGF [40], and acting in synergy with EGF to 
accelerate epithelial wound closure [40]. Il-1α is a master modulator of the wound healing cascade [41] 
and has been linked to fibroblast apoptosis via the induction of Fas ligand mRNA and protein production 
that results in autocrine suicide [77]. TNF-α has also been linked to keratocyte apopotosis [41]. Il-1 
released from the epithelium at the apex of the epithelial cells following apoptosis. It is also present in 
the tears in conditions associated with ocular surface injury [41]. Unwounded keratocytes to not 
produce Il-1α, but the Il-1α autocrine loop is initiated in corneal fibroblasts in response to Il-1 
stimulation [77]. Keratocytes only produce Il-1 when exposed to the cytokine following epithelial 
injury as it cannot pass into the stromal layer as the epithelial barrier functions blocks it. Keratocytes 
exposed to Il-1 enter a self-perpetuating autocrine loop [41] that controls the production of HGF and 
KGF by keratocytes which effectively regulates epithelial healing and keratocyte proliferation and 
apoptosis [69,77] via the Fas-Fas ligand system. Il-1 also initiates the synthesis of collagenases, MMPs 
and other enzymes by keratocytes which are involved in collagen remodeling during healing. Il-1 and 
PDGF are usually only secreted by epithelial cells under physiological conditions, where as their 
corresponding receptors are expressed by stromal cells [46], demonstrating the need for cross-talk 
between cell types.  
Type II cytokines moderate both epithelial and fibroblast cells and include IGF-1 and FGF. IGF 
stimulates keratocyte proliferation and migration [69] whilst maintaining cell morphology, cytoskeltal 
organization, and keratocan sulfate synthesis. It has also been shown to enhance the effects of EGF on 
endothelial cells [39] and exists as a component of tears [69]. EGF mRNA has been detected in all 
corneal cell types [53], and the protein is present in endothelail and epithelial cells, but to a less extent 
in stromal cells [70]. EGF exerts its effects on cells via paracrine, juxtacrine and autocrine 
mechanisms [70]. EGF has been associated with corneal vascularization in some studies, whilst having 
no apparent effects in others [70]. Thus angiogensis via EGF may be linked to its combined presence 
with other growth factors, FGF in particular [70], during wound healing.  
Fibroblasts produce type III cytokines including KGF and HGF which are important signaling 
molecules in regulating epithelial-mesenchymal interactions [52]. KGF and HGF (also known as 
scatter factor [70,78]) both stimulate epithelial cell proliferation in a paracrine fashion [40] by 
activating their corresponding receptors [46]. KGF (a member of the FGF family [69]) stimulates 
growth of limbal and conjunctival epithelial cells where as HGF is involved in the proliferation and 
control of peripheral epithelial cells, with the dominant factor dependent upon the wound site [40]; 
EGF has similar effects and is a known potent mitogen of epithelial cells [70]. It is thought that EGF 
acts as a basic facilitator for epithelial proliferation where as KGF and HGF are up-regulated 
dependent upon the amount of damage [40]. HGF production is increased in the lacrimal gland 
following epithelial injury, and thus this may be the primary source of HGF during early wound 
healing until the fibroblasts/myofibroblasts repopulate stroma [41]. HGF also promotes epithelial 
motility, aiding in the spatial arrangement of the cells [78] and prevents epithelial terminal 
differentiation [46]. The mitogenic activity of KGF is restricted to epithelial cells in vivo where it acts 
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as a paracrine effector [69]. KGF is produced by keratocytes and acts on the epithelial cells by binding 
to KGF-receptors [69].  
During wound healing, the initial removal of the injured tissue is controlled by  
plasminogen-activator/plasmin systems and matrix metalloproteinases (MMPs) [52] which degrade the 
components of the ECM. Plasmin cleaves the proteins of the ECM and initiates dominant enzymes 
such as pro-collagenase and TGF-β. MMPs are zinc-dependent proteinases whose substrates contain 
several elements of the ECM and basement membrane [44] that participate in ECM remodeling and 
angiogenesis (the development of new blood vessels) [52]. MMPs are deposited in a dormant form by 
the resident cells and invading inflammatory cells [40,41] and are organized via tissue inhibitors of 
metalloproteinases (TIMPs). They are vital in embryogenesis, development, and regulate wound 
healing via cell migration and contraction [44]. In a healthy cornea, only low amounts of MMP-2 are 
detected as a proenzyme. However, following injury and cytokine release, many MMPs are upregulated. 
MMP-1 (interstitial collagenase), -2 (gelatinase A), -3 (stromelysin-1) and -9 have all been shown to 
have involvement in epithelization and stromal remodeling [44]. The precise mechanism of MMP 
action remains elusive; however MMP-1 is known to be vital for epithelial migration in vitro [44]. 
MMP-9 has been associated with basement membrane deterioration and MMP-2 and -3 are thought to 
manage lasting stromal remodeling and membrane synthesis [44]. 
Wound models on rabbit eyes were performed by Mulhollend et al. [44] in order to understand the 
healing response following photorefractive keratectomy (PRK) or laser in situ keratomileusis (LASIK) 
procedures. Following wounding MMP-2 and -9 were primarily confined to behind the leading edge of 
the migrating epithelium. This demonstrated that these enzymes may be involved in stromal remodeling 
and/or early basement membrane construction. MMP-2 involvement in stromal remodeling is thought 
to be separate from epithelial repair [44]. MMP-9 is likely to act as a factor in stromal repair as it can 
prompt TGF-β (a dominant modulator of scarring). In studies on knock-out mice MMP-9 has been 
shown to increase re-epithelization and has been associated with basement membrane formation [44]. 
MMP-7 can prevent secondary neovasculation of the wound. MMP-1 activation is thought to be 
crucial to epithelial cell migration and wound closure. MMP-2, -9 and -3 have all been connected to 
keratocyte migration and fibroblast activation at the wound site, construction of basement membrane 
and stromal remodeling [44]. By developing and prompting specific MMP inhibitor the wound healing 
process can be separated and specific stromal responses can be indentified and interrupted, thus 
preventing a fibrotic response whilst conserving epithelialization.  
4.3. Matrix Components 
The majority of the corneal stroma is comprised of Collagen I, V, VI and XII, along with dermatan 
sulfate proteoglycan decorin and keratan sulfate proteoglycans (KSPGs) lumican, keratocan and 
osteogycin [19,79] which form the ground substances of the stroma. Keratan sulfate comprises of 
approximately 50% of all the stromal glycoaminoglycans (GAGs) present in the stroma [19]. 
Keratocytes are the major cell type in a healthy cornea. As of yet there is no single molecular marker 
for keratocytes defined although they do express lumican and keratocan to develop and maintain 
collagen interfibrilliar spacing and fibril diameter [79].  
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Keratocan is a cornea specific protein only expressed in healthy corneas and keratocytes [79]. 
In vivo, following initial injury keratocan expression is lost. It may return during and following the 
healing process, albeit in significantly lower levels than in an uninjured cornea [79]. Similarly, in vitro 
keratocan expression is lost when stromal cells are cultured in the presence of serum [67,79]. 
Lumican belongs to a small leucine-rich proteoglycan family and is a major KSPG [80]. The  
non-glycanated lumican core protein is distributed extensively in numerous interstitial connective 
tissues including the sclera, aorta, cartilage and liver [80]. However, in the cornea it is found in a 
glycanated form, meaning keratan sulfate GAGs (KS-GAGs) have bound to the central protein. This 
binding is thought to be involved in the control of fibril diameter, with the extended KS-GAG side 
chains controlling fibril spacing and corneal hydration required for tissue integrity and transparency. In 
studies on lumican knock-out mice, abnormally large collagen fibrils and disorganized interfibrillar 
spacing occurs [80]. This confirms that the key role of lumican is concerned with maintenance of fibril 
architecture via fibril assembly arrangement and balancing the KS-GAG levels required for 
transparency. It may also act as a regulatory molecule for cellular functions including proliferation, 
migration and prevention of apoptosis in injured epithelium, and modulation of keratocan and 
aldehyedehydrogenase (ALDH, an important modulator of corneal metabolism) expression via 
keratocytes [65,81].  
Decorin is a small leucine rich protein that plays a key role in many cellular tissues in a variety of 
tissues including the cornea [81]. It is the predominant dermatan sulfate proteoglycan in the cornea [82] 
but is also found in the majority of connective tissues. Decorin is expressed in both healthy and injured 
corneas [82] where it interacts with growth factors such as EGF and TGF-β to mediate processes such 
as fibrillogenesis [83], ECM metabolism, cell-cycle progression [81] and remodeling following injury. 
Decorin expression increases significantly in response to injury which has led to it often been 
associated as a marker for corneal fibrosis and scarring [82]. Apparently, decorin is a natural inhibitor 
of TGF-β, a growth factor strongly affiliated with myofibroblast differentiation, that results in corneal 
haze and scarring. It is expected that decorin is able to interact with collagen, thrombospondin and 
inhibit TGF-β expression, thus preventing myofibroblastic differentiation, and effectively reducing the 
fibrotic response [83]. Recently, decorin has been investigated as a potential gene therapy to treat 
corneal haze in vivo [83].  
Scar tissue alters the constituents of the original ground substance of the cornea. The proteoglycans, 
type III and IV collagen filaments and various other proteins and glycoproteins constitute to the ground 
substance between collagen fibrils. They are vital in maintaining tissue homeostasis with regards to 
regulating water content, collagen fibril diameter and spacing and thus ultimately transparency. 
Staining of the proteoglycans [47] has been used to demonstrate changes in the ground substances as a 
result of scarring. For example, in a new scar tissue, the presence of fibrotic markers such as type III 
collagen, fibronectin and α-SMA are increased [75]; enlarged proteoglycan [47,54] fibrils and reduced 
keratocan sulfate expression are observed [47]. These abnormalities have been attributed to increased 
water content and the appearance of vacuoles, which contribute to corneal haziness [47] due to 
disruption of fibril organization [54]. However, differences in wound type, i.e., inflammation, necrosis, 
ulceration and scarring cause different wound healing responses due to differing ultrastructural 
changes [54]. This has been attributed to the differences in the cytokines and growth factors expressed 
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which vary with wound type [79]. However, the healing process can usually be identified by global 
inflammation and swelling [80].  
Healing corneas share many characteristics of the developing cornea in that they both appear to 
have unusually thick collagen fibrils and irregular spacing and primarily synthesize collagen types I 
and V [54]. Heavily opaque corneal scarring has also demonstrated the phenomenon of abnormally 
large fibril diameters. The increase in collagen fibril diameter in response to injury prevents normal 
swelling in the subsequent scar tissue from developing, causing disruption of corneal homeostasis [54]. 
The enlargement of the proteoglycans usually responsible for regulation of fibril spacing may 
physically increase water uptake. Proteoglycans are hydrophilic molecules and their presence may 
increase spacing between the fibrils making them appear larger [54]. However, studies performed on 
bovine corneas [54] demonstrate that intermolecular spacing between collagen fibrils is similar in both 
injured and uninjured corneas. Thus the increase in fibril diameter is not necessarily caused by the 
swelling usually observed during healing that may push the collagen molecules apart. The increased 
fibril diameters may be due to a fusion of adjacent collagen fibrils, caused by a deficit of proteoglycans 
in the newly synthesized tissue [54]. Defects in the mechanism that usually controls fibril diameter, 
mediated via type V collagen synthesis may also play a role.  
In addition, type III collagen is also synthesized in both normal (albeit in low levels) and 
developing corneas [84,85]. Type III collagen is one of the earliest collagens to be laid down during 
growth and regeneration [84]. Type III collagen is associated with the normal adult descemets 
membrane and the corneal tissue of most animal species are able to synthesize type III collagen, 
although the age and physiological state of the cells responsible for synthesis and deposition are 
debated in literature [84]. Expression of type III collagen is initially significantly increased [75] in 
healing corneas, thought to be synthesized and deposited via endothelial derived fibroblasts; however 
it is easily broken down during tissue remodeling [84]. It has been speculated that the intermolecular 
disulphide cross-links within the molecule provide mechanical stability during the initial formation of 
scar tissue [84]. Most corneal fibroblasts express collagen types I and III simultaneously [85]. The 
conditions whereby fibroblasts are able to synthesize type II collagen corresponds with the conditions 
whereby they lose the ability to synthesis keratan sulfate. It is thought that the exposure to proteolytic 
enzymes and fibroblast differentiation affects the initiating type III collagen synthesis [85].  
4.4. Mechanical Stress 
The tensile mechanical strength of the cornea is vital to its function and the mechanical properties 
are essential for linking morphology to mechanical behavior [23,86–88] as fibroblast interactions 
within the collagen matrix are decided partially by the cell-matrix tension state [76]. It is the 
biomechanical and wound healing capacity of the cornea that determines the reproducibility and stability 
of many refractive surgery techniques [23]. The overall biomechanical properties of the cornea are 
complex due to the anisotropic nature of the tissue, i.e., different mechanical properties in different 
directions [1]. The anatomical and regenerative characteristics of the cornea are vital to its function as a 
strong, transparent structure able to protect against intraocular injury [23] without rupture [1]. The highly 
organized and ordered collagen fibril network accounts for the corneas mechanical strength [20,89] and 
load bearing element within the tissue [89]. The interweaving collagen bundles between adjacent 
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lamellae supply vital structural foundations for sheer (sliding) resistance and transference of tensile 
loads among lamellae [23]. The load bearing capacity is concentrated in two main directions; the 
temporal-nasal (side-to side) and superior-inferior directions (up-down) [89]. Collagen fibrils are only 
found in the stroma and Bowman’s layer; hence it is these layers that are vital in provision of the 
cornea’s tensile strength [23]. Stripping of the epithelium, although has biological ramifications, has 
little to no effect on the anterior corneal curvature [23], thus attributes very little to the corneas overall 
tensile strength. The Descemets’s membrane has a relatively low stiffness and so accommodates for 
fluctuations in intraocular pressure which may attribute to the absence of stromal stresses experienced 
by the adjoining endothelium [23]. The Bowman’s layer is an 8–12 µm layer that consists of randomly 
orientated collagen fibrils [90]. Extensiometry testing whereupon the Bowman’s layer was removed 
resulted in negligible mechanical changes of the cornea, thus the mechanical properties of the cornea 
are stromal layer dominant [23]. 
The cornea acts as a scaffold for the refractive surface of the eye, thus every mechanical or 
biological reaction to disease and/or injury have an impact on visual acuity [23]. For example, when 
the cornea becomes dehydrated, the stress is distributed largely to the posterior layers or regularly over 
the whole cornea [20]. In a healthy or edematous (swollen) cornea, the anterior lamellae assume nearly 
all of the strain [20]. Stress within the tissues is connected with intraocular pressure. Keratorefactive 
treatments and corneal disease may alter the biomechanical properties directly or indirectly [20].  
The algorithms and models that many refractive ablation techniques are dependent on generally 
assume that the cornea is biologically and biomechanically passive, thus all patients outcomes should 
be predictable and alike [23]. However, this is evidently not the case as the cornea often has a fibrotic 
response to incisional and ablative procedures. Biomechanical deviations become apparent with changes 
in corneal shape, shape instability, enhanced sensitivity, changes in hydration, hypoxia (oxygen 
deficiency) and injury as a consequence [23]. During scarring, deposition of abnormal tissue reduces 
transparency whilst disorganized loss of the remaining tissue causes a loss of tensile strength [52]. 
In vivo, large fluctuations in mechanical phenotype caused by ECM tension can be generated via 
lacerating injury, PRK and refractive surgery techniques [68]. Additionally cell matrix tension state is 
controlled by collagen density, matrix restraint and growth factor environment [76].  
During healing, the initial matrix is less dense, disorganized and more flexible than uninjured tissue. 
ECM composition, stress and stiffness can all alter the cell phenotype both in vivo and in vitro. For 
example, increasing ECM stiffness in vitro is known to up regulate myofiroblastic transformation, 
mimicking what occurs in vivo as myofibroblasts develop towards the end of the wound healing 
process when cell density is high and the wound environment is stiffer [68]. The increased cell-matrix 
tension causes fibroblasts to display stress fibers, focal adhesions and activate focal adhesion signaling 
via phosphorylation of focal adhesion kinase [68,76]. This response is absent when cell-matrix tension 
is low, i.e., in a healthy cornea as from a mechanical point of view quiescent non-activated keratocytes 
do not generate stress fibers or vast contractile forces [17]. The dynamic mechanical feedback existing 
between cells and the surrounding matrices in three dimensional (3D) in vitro cultures occurs due to 
time-dependent ECM remodeling, and may facilitate patterning during embryonic development as well 
as during wound healing [17].  
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5. Refractive Surgery and Scar Tissue 
With the trend occurring that most individuals will at some stage in their life go on to develop some 
form of refractive error, ophthalmic surgery needs to develop and progress in order to provide 
sufficient treatment for preserving or restoring vision. Jose Barraque first recognized that small 
changes in the curvature of the cornea can dramatically affect its refractive ability, and in 1976 
introduced the first lamellar refractive surgery techniques [91]. Photoablastion of corneal tissue was 
reported by Trokel et al. in 1983 [92] and showed evidence of changes to the refractive power of 
damaged corneas. Since then, variations of refractive surgery techniques have come into practice, with 
the common aim to alter and improve the refractive power of the cornea. Photoreactive keractectomy 
(PRK), Laser subepithelial keratomileus (LASEK) and Laser in situ keratomileus (LASIK) are all 
types of refractive surgery to the surface of the cornea and involve removal of corneal tissue. 
Differences in procedures occur with the subsequent treatment of the epithelium [91]. Laser thermal 
keratoplasty (LTK) and conductive keratoplasty (CK) include heat generation to shrink the corneal 
stromal and central corneal steepening [91]. Radial keratotomy can be used to flatten the cornea via 
number of radial incisions.  
5.1. Refractive Surgery Techniques 
Thermalkeratoplasty (LTK) and conductive keratoplasty (CK) heat the cornea to a critical 
temperature of 58–76 °C inducing collagen shrinkage, thus altering the corneal curvature to make it 
steeper [20]. The uses of such techniques are reserved for treatments of the mid periphery cornea. LTK 
is a non-contact treatment whereby a holmium laser is used to heat the corneal collagen. CK is a 
contact treatment involving the use of a radiofrequency diathermy probe inserted directly into the 
cornea [20]. Both techniques have problems associated with local necrosis if the temperature is too 
high and if the heat source is not consistent or uniformly administered, variable astigmatism (unequal 
corneal curvature) arises [20].  
Radial keratotomy (RK) is an incisional technique used to treat myopia and hyperopia. However, 
the technique is often superseded by excimer laser treatments. It continues to have a role in the 
treatment of primary and residual astigmatism following cataract keratorefractive surgery and 
photorefractive keractectomy (PRK) [20]. RK differs from surface ablation and LASIK procedures in 
that it excludes the removal of tissue from the central cornea. The procedure includes making tiny cuts 
in the cornea, which flattens it, reducing the curvature of the cornea [91] and decreasing the refractive 
power [20]. Drawbacks affiliated with RK include daily fluctuations in vision and excessive flattening 
of the cornea due to a regression of the intended central corneal flattening effects caused by a 
contractile mechanism being initiated during wound healing [61]. Additional problems include mild to 
moderate irregular astigmatism leading to visual distortion and glare, particularly in patients with more 
than 8 incisions [20]. 
Photorefractive keratectomy (PRK) was the first form of laser ablation [91] that permanently alters 
the refractive power of the eye using an argon fluoride laser with predictable outcomes and is 
commonly used to treat myopia [47]. In corrective PRK a wound is created via mechanical epithelial 
debridement and surgical removal of the corneal disc [47], followed by laser ablation of the basement 
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membrane and anterior stroma [10,46], leaving a smooth wound remaining. This encourages corneal 
flattening as most of the corneal tissue is removed centrally, with less removed around the peripheral 
area [91]. Initially the technique was favorable over RK as it appeared that following the PRK 
procedure that corneal mechanical properties are maintained and an increased reproducibility between 
patients was observed [47].  
Laser in situ keratomileusis (LASIK) or Epipolis LASIK (Epi-LASIK) is currently the prevailing 
refractive surgery [91]. During LASIK the epithelium is mechanically separated below the basement 
membrane and just above the bowman’s layer. It is favorable to PRK as the epithelial layer and cells 
are well preserved and so act as a protective layer preventing exposure to tears and the ablated stroma. 
This is important as tears contain the growth factors and cytokines associated with fibrotic response 
and scarring. LASIK surgery also bypasses the pain and extensive visual recovery associated with 
PRK procedures and can be used to treat higher degrees of myopia [91]. Furthermore it is sometimes 
favorable to LASEK as it negates the need for potentially toxic alcohol contacting the epithelium and 
stroma. However it is by no means a perfect technique as sometimes epikeratome flap failure often 
warrants a conversion to PRK [1,91] 
Laser subepitheial keratomileusis (LASEK) was originally called alcohol assisted flap PRK as it is 
a combination of PRK and LASIK techniques [91]. The technique involves the chemical reduction of 
the adhesion molecules that attach the epithelium to the Bowman’s layer. A marking trephine 
(cylindrical blade) 8–9 mm in diameter is placed onto the surface of the cornea and a dilute alcohol 
solution is added to loosen the epithelium [91]. Cold balanced salt solution is used to wash away the 
alcohol. The corneal mark left by the trephine is dried with a surgical spear to aid delineation (marking 
of the outline). The epithelium is lifted and peeled back as a complete flap and the surface of the 
cornea is dried and ablated with an eximer laser. The epithelial layer is then repositioned and a bandage 
contact lens covers the wound for 3–5 days allowing for re-epithelialzation [91]. LASEK is sometimes 
preferred by patients over LASIK as it has a lower risk of corneal estacsia (loss of substance and 
scarring, resulting in a bulging of the tissue) [91] and a faster healing and rehabilitation period [91]. 
However, LASEK has been associated with patients experiencing pain following surgery. Cold-balanced 
salt solution and systemic steroid treatments have all been employed to help alleviate this.  
5.2. Associated Scar Tissue Formation 
It has been reported that RK-induced wounds can differentiate keratocytes into myofibroblatic cells 
which are responsible for wound contraction [61] and scarring. Light scattering from the radial 
incisions and/or scars may lead to “starburst” patterns occurring around lights at night, which can 
make driving hazardous. Mitotic agents including brimonidine and pilocarpine can be used as a 
temporary treatment as they shrink the pupil, thus blocking light from the peripheral cornea where the 
incisions are located [20]. Pain following surgery, under- and over-correction, vascularization and 
endothelial disruption due to the incisions are all attributed to RK surgery. Perforation of the cornea 
occasionally arises, leading to endothalmitis (inflammation of ocular cavities), epithelial down growth 
and cataracts [20].  
Similarly, follow up studies demonstrated that PRK is only analogous to RK as following the 
primary period of overcorrection; rapid degradation (usually within the first two months) to a relatively 
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constant refraction can lead to corneal scarring, glare and a decrease in visual acuity. The regression in 
refraction is caused by the normal reaction of the cornea to injury whereby regeneration of the tissue 
occurs in an attempt to restore corneal integrity following the removal of the anterior epithelium [47]. 
Laser ablation effectively damages the tissue. The removal of the bowman’s layer causes a 
pseudomembrane to immediately form (usually within 3–5 days), which covers the ablated area with 
3–5 cell layers (a healthy epithelium usually contains 5 to 7 cell layers in humans) [1,79,91]. Activated 
epithelial cells, fibroblasts and macrophages migrate towards the wound site in order to remove the 
damage tissue and remodel the affected tissue. The keratocytes beneath the basement membrane 
undergo apoptosis, typically in the superficial region. Invading inflammatory cells come from the tear 
film and activated keratocytes (fibroblasts) form new collagen and a proteoglycan matrix, followed by 
the disappearance of the pseudomembrane [91]. However, in PRK procedures performed on rabbit 
corneas apoptosis has been observed up to 85 μm into the stroma [10,59]. In PRK studies performed 
on rabbits, monkeys and humans the degree of scar tissue formation has been linked to the ablation 
depth, i.e., more scarring occurs with greater ablation [47]. The accuracy of the procedure is described 
as the percentage of eyes within ±1.0 diopters of the intended refraction [47]. This results in a natural 
predisposition towards an increased accuracy for the improvement of low refractive errors, i.e., the 
larger the attempted correction, the lower the accuracy.  
Considerable variations in subsequent scarring causes light scattering and corneal haze [23] 
approximately 1 month post surgery, which can increase in severity up to 3 months [91]. The 
definition of corneal haze varies considerably in the literature possibly due the largely empirical 
approach of determining success rates. The severity of haze is graded from 0 to 4. A 0 score is an 
optically clear cornea, where as a 4 indicates an opaque cornea which is visible to the naked eye. Often 
corneal haze resolves, unaffecting vision, but in more serious cases, results in the loss of unaided 
visual acuity [91]. A number of treatments have been investigated with the aim to reduce corneal 
haziness following PRK. The application of corticosteroids is known for their ability to inhibit corneal 
stromal healing and have been used in PRK experiments to reduce the deposition of scar tissue [47]. 
Topical steroids are also used to prevent macrophage and lymphocyte intervention in the wound site, 
reducing collagen deposition by fibroblasts. Anti-metabolites (a metabolite inhibitor) including  
5-fluorouracil and mytomycin-C are used to increase the effect of topical steroids as they help to 
prevent fibrosis. However, toxicity concerns emerge regarding both epithelial and fibroblast cell 
viability, which can impede epithelialization. In-depth, long-term follow-up studies regarding 
refraction are infrequent in literature. 
5.3. Summary 
Refractive surgery techniques are ever growing in use and popularity. However, as of yet there are 
no imminent, continuous follow up studies published for many of the techniques. Existing long-term 
follow up studies (CK and RK) are discouraging and highlight procedural instabilities and corneal 
regression [20] such as epithelial hypertrophy is a common problem often requiring further “touch up” 
procedures [79]. Photoreactive keratectomy and laser in situ keratomileusis are being improved but are 
often criticized for using largely empirical approaches [3]. Three generalized patterns of healing have 
been noted with regard to refractive surgery techniques. A faint reticular haze occurring in the 
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subepithelial space is observed in type I healing. This usually ceases 1–3 months following surgery. 
Subepithlial haze does not occur in type II healing, but hyperopia (long sightedness) occurs which 
often requires additional epithelial debridement or further refractive surgery. In fact, 5%–20% of all 
patients having had refractive surgery require secondary treatments in order to accomplish a 
satisfactory result [91]. In type III healing a substantial subepithelial reticular haze occurs which is 
observed on the cornel tissue, frequently combined with an advance in myopic shift (also a symptom 
of cataract formation). All keratorefractive techniques cause a refractive change via alterations in 
corneal curvature [20]. Corneal ectasia (loss of substance and scarring) is an acknowledged 
development associated with refractive surgeries. Large ablation depths, high myopic treatments, thin 
remaining stromal thickness and touch-up treatments all increase the risks of developing ectasia. 
Ideally, photoabalative treatments should not initiate new optical problems. The reduction in corneal 
thickness often as a result of the surgeries has significant drawbacks concerning intraocular pressure 
and glaucoma screening and management [91]. In addition, corneal surgery has been criticized for 
being unpredictable resulting in over or under correction, or the development of antagonism [3]. Such 
results are predominantly due to the lack of knowledge. Further progress in the understanding of 
wound healing and post operative pain management are continuous challenges [91]. Appropriate 
corneal models have the potential to fill the voids in knowledge in order to improve current treatments 
of corneal disease, which could lead to a reduction in the demand for corneal transplantation. 
6. Corneal Grafts and Corneal Tissue Engineering 
The change in corneal curvature elicited by external surgeries or removal of corneal issue, no matter 
how small, inevitably provokes a wound healing response. Currently, the only truly successful 
treatment available for many corneal diseases is corneal allografting. Although the cornea is immune 
privileged, transplantation carries many risk factors. There are numerous alternatives that are being 
investigated in order to replace donated tissue [89], or to possibly suppress the demand for donated 
tissue [93]. Amongst these are xenografts, keratoprostheses and tissue engineered corneas.  
6.1. Corneal Allografting 
Corneal allografting is often referred to as corneal transplant, keratoplasty or penetrating 
keratoplasty (PK). The graft replaces the damaged central corneal tissue with healthy corneal tissue 
from the same species. Unlike other forms of tissue transplantation, corneal allografting are routinely 
performed without the aid of prior tissue typing or systemic immunosuppressive drugs. The cornea and 
corneal allografts are often referred to as immune privileged due to its avascular nature [94], however 
clinicians often object to this proposition as immune rejection is the leading cause of corneal graft 
failure and remains as a barrier to successful transplantation [94]. Corneal allografts are in fact 
immunogenic (capable of inducing alloimmune responses) and antigenic (susceptible to antigen 
specific responses by alloimmune effectors). The rate of corneal graft rejection is variable amongst 
studies and may be due to differences in patient population, diagnostic rejection criteria and 
immunosuppressive treatments [95]. The success of corneal transplantation does not compare to the 
improvements in outcome seen in other clinical transplantation procedures [96], with graft failure most 
common in patients who have received grafts for conditions other than keratoconus (conical cornea) or 
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stromal dystrophies [96]. The success rates in such patients in considerably lower than the survival of 
solid vascularized organs, with so far no evidence of improvement [96]. Grafts onto inflamed recipient 
corneas reject most frequently and rapidly [96]. Once inflamed, a cornea is never the same with 
regards to immune privileges. Rejection of the donor endothelium is the principal source of transplant 
failure. Rejection of allograft materials most commonly occurs within 4–18 months post 
transplantation, but can be seen anytime following surgery [95] sometimes years after surgery [94]. 
Risk factors that lead to graft rejection involve surgery technique (loose sutures and premature suture 
removal), the extent and severity of vascularisation in the recipient, the number of regrafts, bilateral 
grafting, inflammation, glaucoma, dermatitis and dry eye conditions [95]. Alternative approaches are 
required which account for the unique responses to corneal allografting.  
Ultimately, it is the lack of suitable donor tissue and high graft failure rates that warrant the need for 
alternative procedures [18,89] particularly in patients where immunological privileges are reduced [96] 
and additional suitable grafting materials. The successful generation of suitable corneal replacements 
could reduce the demand on eye bank tissues whilst also aiding in the generation of more effective 
drug and therapeutic treatments.  
6.2. Xenografts 
Xenografts are when tissue(s) from one species is transplanted into a different species; for example, 
a tissue of bovine, porcine or non-human primate origin transplanted to humans [97]. Xenografts have 
advantages compared to allografts in that it offers a virtually unlimited tissue source and scheduling is 
impendent of the availability of a human donor [97]. Porcine corneas are commonly used as they have a 
similar physiology to human corneas and are relatively easy to obtain [98]. The prevailing problem 
concerning xenografts is interspecies differences leading to graft failure and disease transmission [8,97]. 
Reports of corneal xenotranplantation models often show different results in different species, so the 
mean survival time varies from days to months [98], but all eventually fail due to immune response. 
Glucocorticoids are often used as immune suppressants as they block inflammatory mediator release 
and inhibit cytokine production. However, more research into immune suppression following surgery 
is still required as the precise mechanism of corneal xenografts rejection is still unknown [98].  
Commonly the rhesus monkey is used in xenotransplantation studies as it shares anatomical, 
histological and immunological responses to humans, thus can act as a predictor of clinical performance. 
However they may not faithfully represent what would happen if a porcine organ was transplanted into 
a human subject because non-human primates may develop immunity against human proteins 
expressed in pigs [98]. Studies have been made looking at the possibility of using porcine corneas for 
human grafts [8,99]. However the initial results were poor potentially due to the small but significant 
structural differences between animal and human corneas. In summary the risk of cross-species disease 
transmission has given the public a poor perception of xenografts; thus this technique will probably 
never develop further than pre-clinical stage research.  
6.3. Keratoprostheses 
Keratoprostheses were essentially the first form of artificial corneas developed [6] and offer hope to 
patients with dry eye conditions such as severe ocular surface disease, chemical burns or corneal 
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vascularization [100]. Surgery is usually only offered to patients with bilateral corneal blindness or 
those unsuitable for allografting [28].  
A keratoprosthesis is an acellular artificial implant that ideally should be biologically, mechanically and 
functionally anchored to the eye tissues without biological and mechanical adverse side-effects [101], 
permit light transmission in the visible range and protect the retina from UV damage [1]. Materials 
including glass, fiber glass, silicone, nylon, cellulose [102], poly(vinyl alcohol) (PVA) [101], Darcon 
fabric [101], Teflon [102], and hydrogels have been examined for the keratoprostheses use. The 
majority of keratoprostheses are based upon a transparent central optic, surrounded by an anchoring 
“skirt” that promotes cellular integration from the host [6,28] (Figure 5). A keratoprosthesis that has 
undergone clinical trials is AlphaCor™ originally known as the Chirilia Keratoprosthesis [103,104]. 
AlphaCor™ comprises of cross linked poly(2-hydroxethyl methacrylate) (pHEMA), which is one of 
the most extensively examined materials for keratoprostheses. AlphaCor™ has been implanted into 
human patients with promising results achieved [104]; however, patient maintenance of the devise is 
principle to its success post surgery [1].  
Figure 5. A schematic diagram of an atypical keratoprosthesis 
 
The Boston Type 1 [100] is a commonly used keratoprosthesis in the United States that has 
undergone clinical trials. It consists of two plates made from poly(methyl methacrylate) (PMMA) with 
a titanium locking ring to hold the back plate in place. PMMA is the most frequently used material and 
can be made in UV absorbing forms for intraocular lenses. It can be shaped and preserves clarity 
whilst having low toxicity [1], but its rigidity and hydrophoboicity lead to poor diffusion. 
The procedure to implant a keratoprosthesis is complicated and to date, clinical use of 
keratoprostheses has been little. There still needs to be a great deal of research and improvement made 
in this area before keratoprostheses are used to replace donated corneas in corneal transplants [1]. 
Despite huge advances in the technology used, biocompatibility is still an issue [102,105] as many of 
the materials are non-cell adhesive so improvements need to be made to modify the ability of corneal 
cells to adhere and migrate over the surface [6]. Biological compliance and attachment of prosthetic 
devices relies upon the ability of stromal cells to migrate into the device and deposit matrix [1]. 
Epithelization is one of the most demanding features that need to be considered when producing a 
keratoprotesis, as often the act of blinking can shear away the epithelial cells on the transplanted 
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prostheses [1]. Keratoprothesis devises are generally more successful when the descements membrane 
is intact [1] however; severe eye conditions have often damaged or destroyed it. Failure of a prosthesis 
to correctly anchor can lead to extrusion or protrusion of the implant [28,102] which in turn can affect 
mechanical strength [8,106].  
6.4. Tissue Engineered Corneas 
Tissue engineering (TE) can be described as “the production of biological or semi-synthetic living 
tissue for use as replacement tissues for damaged or diseased tissues” [107]. Technically speaking, it is 
the generation of a tissue by seeding isolated, specific cells or stromal cells into or onto a template 
(often referred to as a scaffold) and culturing it in a dynamic environment with the aim to eventually 
form a tissue which mimic the morphological, physiological and biochemical properties of the natural 
tissue as closely as possible [107]. The idea of a bioengineered cornea has emerged with corneal 
counterparts being assembled from corneal cell lines [1]. With respect to corneal tissue engineering 
there are many challenges that need to be addressed, not least the fact that the structure of the cornea is 
unique and difficult to replicate. Two fundamental challenges in corneal TE are the maintenance of 
phenotype in isolated stromal cells and the replication of the collagen architecture. If both factors are 
not satisfied, the result is often a regenerated tissue mimicking that of scarred native tissue. Thus far, 
advances in the development of a fully bioengineered cornea are still at an analytical stage [1]. At 
present when attempting to construct a TE-cornea tissue strength and transparency are the main areas 
of focus as these are lacking in current models [108].  
When constructing a tissue-engineered cornea, the choice of scaffold material is vital [109,110] in 
order to enable the cells to behave and form the complex arrangement as they would in in vivo. 
Amniotic membrane, collagen, fibrin, cross-linked fibronectin-fibrin gels, gelatine-chitosan,  
collagen-glycosaminoglcan blended nanofibrous scaffolds, contact lenses and thermoresponsive 
polymers are amongst the vast assortment of materials investigated as suitable corneal substrates [111]. 
However, as of yet few have achieved clinical approval [111]. The list of requirements for a suitable 
scaffold is extensive, as they must be biocompatible [93], optically transparent, strong as to withstand 
manipulation in culture, potential suturing, irrigation and handling in surgery. The material also needs 
to be flexible to take the shape of the eye and lay flat on the surface. It needs to be able to be produced 
easily with consistent quality, preferably at high speed and low cost [112], have controllable 
biodegradability or bioresorbability enabling cultured tissue to replace the scaffold material [110] and 
have the spatial architecture of the native tissue. There are various arguments as to whether natural or 
synthetic biomaterials are more suitable. In general, the properties of native soft tissues are not easily 
duplicated by synthetic materials [113], as the cells do not recognize the surfaces, so do not attach [110]. 
In vivo cells thrive on ECM comprised predominantly of collagen, glycoproteins, proteoglycans, 
laminin and fibronectin.  
In order to successfully achieve a tissue engineered corneal substitute the ability to successfully 
culture epithelial, keratocytes and endothelial cells that will proliferate in culture conditions whilst 
retaining most of their in vitro characteristics is required [56]. Currently we and other groups recognise 
that the culture of pure corneal cells is problematic [114], and that the optimal culture conditions of the 
isolated cells need to be defined and optimized. It has already been established that keratocytes differ 
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in a variety of ways from fibroblasts and myofibroblasts. Cell morphology, proliferation and the 
expression of gene products are identifiable as being significantly different [57]. Phenotypical changes 
occur when a cell becomes fibroblastic and it has proven difficult to reverse such changes when 
attempting to culture keratocytes in vitro. Studies have suggested that it is possible to culture keratocytes 
in culture whilst retaining their in vivo phenotype [57]. Previous investigations have also claimed that it 
is possible to de-differentiate corneal myofibroblasts back to their fibroblast phenotype [57]. However, 
the main challenge still remains for researchers to differentiate fibroblasts to a keratocyte phenotype. 
The successful differentiation would be hugely significant with regards to corneal transparency in vivo 
and in vitro. Transparency can be restored in corneal scar tissue in vivo suggests that fibroblasts are 
capable of returning to the keratocyte phenotype and replacing the disorganized ECM of the scarred 
tissue [57]. The suppression of scar tissue formation is the general strategy employed for functional 
corneal tissue formation. In vitro manipulation of chemical, topographical and cellular environments 
may enable us to mimic the conditions required to do this. 
6.4.1. Manipulation of Chemical Cues 
Chemical cues supplied by culture media and supplementation can influence cell phenotype 
in vitro. This is not specific to corneal cells but is true for most cell types. Successful culture of 
keratocytes is imperative for restoration of corneal transparency in stromal equivalents. Many studies 
demonstrate that when cultured in serum-free media corneal stromal cells maintain a quiescent cell 
phenotype associated with keratocytes [55,57,62,115]. However quiescence behavior alone is not 
sufficient in determining keratocyte phenotype as it is not unique to the keratocyte phenotype [55]. 
Often, the quiescent behavior of cells due to removal of serum is followed by apoptosis [67]. Thus 
supplementation is required in media that can promote cell growth and proliferation of keratocytes 
without encouraging fibroblastic differentiation [67].  
Studies performed using primary cultures of bovine keratocytes [57] have shown that the presence 
of serum causes the cells to turn fibroblastic [57]. The addition of TGF-β without serum can also cause 
the same result [55,57]. It was hypothesized that the removal of serum would cause the cells to 
differentiate towards a keratocyte morphology. Following 8 days culture in serum free media the cells 
did in fact return to a morphology that was keratocyte-like in appearance and it was also suggested that 
the surrounding ECM was also restored to a keratocyte profile. Unfortunately the levels of aldehyde 
dehydrogenase (ALDH3)-a cytoplasmic protein vital to corneal transparency did not return to levels 
expressed in keratocytes. This promising study suggests that the partial restoration of the keratocyte 
phenotype following a fibroblastic transition is possible. Unfortunately the addition and removal of 
serum from media is not enough to fully restore the full phenotypical profile of a keratocytes and more 
complex biochemical cues still need investigation.  
The list of biochemical components included in “keratocyte media” in current literature is extensive 
and often contradictory. Acetycholine, insulin [56], vitamin C [13,108] growth factors [56] and 
cytokines [55] are but a few amongst many supplements that have been investigated when attempting 
to obtain a “pure” proliferating culture of keratocytes. It should also be noted that often studies that 
look at the effect of biochemical cues are performed under simplified two dimensional (2D) tissue 
culture conditions. Interactions between the keratocytes and competing environmental stimuli are not 
J. Funct. Biomater. 2012, 3            
 
 
670
considered [55]. Multiple growth factor and ECM signals may be important to keratocyte differentiation. 
Thus a 3D environment may be required in order to more closely mimic the environmental cues required 
to successfully culture and between keratocytes and its sub-types.  
6.4.2. Utilizing Topographic Cues 
Native corneal tissue primarily consists of collagen type I. Collagen type I hydrogels commonly 
used in tissue engineered tissues as scaffolds formed by conventional thermal gelation often have poor 
mechanical strength and lack organization, which is contrary to the characteristics of native stroma [116]. 
Naturally, keratocytes grow in an orthogonally arranged architecture, following the organization of the 
collagen fiber bundles. Much research has focused upon mimicking this architecture in both 2D and 
3D cultures. Contact guidance techniques have been extensively researched as they are able to affect 
many cell characteristics including orientation, morphology, differentiation and secretion of ECM 
proteins [89]. It is the material composition and more specifically the 3D nano- and microscale 
structure (the mesostructure) of bioartificial constructs that are pivotal to their success [117]. Micro- and 
nano-patterned surfaces, magnetic alignment and electrospinning techniques are amongst a variety of 
techniques utilized in order to achieve this. 
6.4.3. Micro- and Nano-Patterning 
Micro- and nano-patterned surfaces have been thoroughly investigated when attempting to mimic 
the corneal fibrillar arrangement [89]. They are often manufactured via the use of templates with well 
defined groove widths and depths into which cells with and without matrix materials are added [89]. 
The patterned surfaces effectively restrict random cell growth via the incorporation of either physical 
or biochemical barriers. Orientated deposition of ECM components is capable of reinforcing the 
substrate in a given direction, which enhances the global mechanical properties of the original 
construct [89]. Vrana et al. [89] demonstrated the ability to align both cultured stromal and retinal 
pigment epithelial cells onto micro-patterned collagen films. The cultured stromal cells showed 
increased cell and ECM orientation and elongated morphology for up to 7 days culture duration. 
However, following 3 weeks culture the cell orientation decreased. This was attributed to the fact that 
the cells were able to adhere to the inclined walls of the micro-patterned surfaces following 
proliferation and thus filled the space at the base of the aligned channel. The epithelial cultures 
however, failed to secrete significant ECM proteins and showed reduced proliferation. Fibroblast and 
epithelial ECM secretions are different, but it has been demonstrated that surface patterning can impede 
extensive cell-cell contacts characteristic of epithelial cells, which alters proliferation capabilities [89].  
6.4.4. Magnetically Aligned Collagen 
Magnetic fields have been utilized in an attempt to create a stromal like-scaffold made up of 
multiple intermeshed orthogonal layers of orientated collagen I fibrils [26]. The use of magnetic fields 
to induce collagen orientation is advantageous in that it is non-destructive [26]. It has been reported 
that molecules of collagen can be assembled into orientated fibrils via the application of a magnetic 
force [26]. In brief, this can be achieved by loading an aliquot of collagen into a shallow sample holder 
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and positioning it horizontally in the central region of a split coil superconducting magnet and 
increasing the temperature from 20 to 30 °C for approximately 30 min. The collagen molecules 
assemble into orientated fibrils perpendicular to the applied field and transform into a viscous gel that 
is stable and orientated after the magnetic field is removed. The orthogonal arrangement is achieved by 
adding more collagen and repeating the process at an altered angle, in a layer-by-layer approach. 
Human keratocytes can then be successfully seeded onto the aligned surface of the gel where they then 
become uniformly aligned along the collagen fibril direction [26].  
Although the author claims that the orthogonal scaffold produced using this method are structurally 
similar to a native stroma they are flawed in that they are not highly transparent. Lack of transparency 
could be due to the fact that the fibril diameter is much greater than would be found in a native cornea, 
approximately 100–200 nm, in comparison to 20–30 nm. The addition of proteoglycans has been 
shown to reduce fibril diameter thus increasing transparency [26], but unfortunately no systematic 
study has been performed to fully understand and exploit this phenomena. Unfortunately fibril 
diameter cannot be regulated when using such a technique. 
Despite the claims of this promising technique being used to form the basis of a corneal implant for 
corneal regeneration, there has been very little literature published since for in vitro cornea 
applications. There is also conflicting evidence suggesting that the application of strong magnetic 
forces can in fact impair cell function and viability [26,118]. It should also be noted that the 
keratocytes were only added to the collagen construct after the gel had been aligned and set as the 
technique is non-sterile. So it is questionable as to whether the cells are able migrate through the full 
thickness of the construct as they would in a native cornea.  
6.4.5. Electrospinning of Nanofibers  
Electrospinning is a century old process that is able to produce continuous fibers from the 
submicron diameter down to the nanometer diameter [119]. These fibers can then be arranged to 
recreate the microstructure and arrangement of the collagen fibers in a natural cornea. Typically 
collagen type I solutions are combined with a synthetic polymers such as polyethylene oxide (PEO) or 
1,1,1,3,3,3-hexafluro-2-propanol (HFP) as a solvent. However, HFP is difficult to work with and toxic 
so it could be argued as to whether it would be a suitable or safe material for tissue engineering 
applications [112]. No one as of yet has created aligned type I fibers on a small enough size scale 
comparable to those in the native cornea [18]. It has been shown in 2D culture conditions that keratocyte 
populations are able to align in multiple adjacent layers arranged 30–90° to each other [108,120]. 
Wray et al. [18] and Wu et al. [121] have previously used aligned collagen and poly (ester urethane) 
urea fibers fabricated by electrospinning, to grow corneal stromal cells. However, these studies were 
limited to a single dense nanofiber sheet and did build the full organization similar to that of the native 
tissue. In order to generate a functional corneal tissue, a 3D environment with defined topographical 
cues throughout a 3D construct is required [67].  
Wray and Orwin [18] report that they have managed to recreate smaller fibers without the use of 
toxic solvents or polymers which support the growth of corneal fibroblasts and encourage the cells to 
align along the fibers. However, they did not comment on cell morphology, culture duration, or if the 
fibers induced differentiation of the cells. Only corneal fibroblasts were reported to grow along the 
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fibers in this study which as previously mentioned are not actually found in the native healthy cornea 
and are significantly easier to cultivate, expand and manipulate in culture than cells native to the 
healthy cornea. It has not been determined how the fibers affect transparency of the aligned fibrous 
scaffolds neither.  
It has already been shown that the three main corneal layers can be recreated in vitro using 
collagen-based scaffolds [5]. However these models are still lacking the highly organized 3D collagen 
based architecture that is present in a native stroma [26]. Thus the biomechanical and optical properties 
of the cornea models are compromised as it is the collagen fibrils that reinforce biological materials [21]. 
By improving collagen orientation so that it is more organized, as in a native cornea, would result in 
improvements in both optical and mechanical properties and so is an area that future research needs to 
pay more attention to. The ability to construct a scaffold that has orthogonal lamellae of aligned 
collagen fibrils is desirable in the development of tissue-engineered corneas [26] and has yet to be 
successfully achieved. It is also interesting to note that the majority of corneal diseases result from 
disruption of the highly organized collagen fibril arrangement in the stromal layer [3]. Thus if a more 
accurate corneal model that incorporated the corneal fibril organization into their design were 
produced then it could be used by corneal surgeons to more accurately predict the outcome of surgical 
procedures. Scaffolds able to mimic the native corneal organization may be beneficial as they create a 
strong tissue substrate that may accelerate the healing process, aid orientation of the subsequent 
secreted ECM and increase the tensile strength [67] that is often lacking in artificial constructs. When 
used in combination with chemical manipulation of culture conditions the use of aligned electrospun 
nanofibers arranged into orthogonal 3D layered constructs has also been shown to change the cell 
phenotype of contractile stromal fibroblasts towards a quiescent keratocyte lineage, which display a 
more elongated dendritic morphology and express genetic markers characteristic of the native 
keratocyte phenotype [67].  
The incorporation of electrospun nano-fibers into corneal tissue engineering is a technique that is 
still in its infancy and evidently needs a lot more research before it can feasibly be used as a way of 
mimicking fibril orientation in in vitro corneas. It is however a potential avenue for future exploration 
and improvement.  
6.4.6. Co-Culture Approaches 
There are numerous cell based approaches that have been reported, all with the similar aim to 
manipulate the cells to create their own ECM so that they behave the way that they would in a natural 
cornea. There is a great deal of information in the cells themselves that needs to be understood as is the 
cells that contribute to the transparency and strength of the cornea. The majority of culture systems for 
corneal tissue separately culture epithelial cells, keratocytes/fibroblasts and endothelial cells as  
mono-layer cultures [122]. 2-Dimendional (2D) monolayer cultures have been used to investigate the 
way that various exogenous growth factors can be used to regulate growth, differentiation and function 
of corneal cells [123]. However, monolayer culture fails to mimic the in vivo physiological 
environment and lack the 3-Dimensional (3D) physiological environment found in vivo tissues and so 
are often criticised with regards to their limited application to the in vivo situation [124]. 
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Most tissues consist of more than one cell type and it is the organisation of the cells within the 
tissue that is essential to normal development, homeostasis and in the case of corneal tissue, 
transparency. In vivo, epithelial cells are in close contact with keratocytes [125,126] in the stromal 
layer; they are connected both anatomically and functionally [77]. Co-culture studies aim to recapture 
this cellular anatomy and functionality. It has been suggested that that epithelial cells proliferate more 
actively and are better differentiated in co-culture systems with keratocytes and endothelial cells than 
when in separate cultures [122] and their proteoglycan synthesis is significantly less in monocultures 
than when cultured as a whole intact cornea or in a co-culture system [127]. This may be due to the 
production of as-of-yet unknown (combinations of) growth and differentiation factors that affect the 
growth and proliferation of the cells [122]. It has been suggested that growth factors and cytokines 
secreted by epithelial cells regulate keratocyte cell function and vice versa [46,65] in a reciprocal 
bidirectional manner that aid and stimulate normal migration and the secretion of proteoglycans and 
glycoaminoproteins in a simultaneous, highly coordinated manner which changes dependent upon 
development, homeostasis and wound healing; although direct cell-cell communications do occur in 
some situations [128] that are vital to cell response [54]. This interaction is critical in in vivo wound 
healing and may have important connotations for in vitro co-cultures. Differentiation in the cornea 
involves multiple growth factors, cytokines and extracellular environmental signals [55], thus a 3D 
environment is often required to mimic the extrinsic environmental as well as the intrinsic cellular cues 
necessary to successfully culture and differentiate stromal cells and their subtypes. In vivo it is the 
interactions between the keratocytes and adjacent epithelial cells that are vital to maintaining tissue 
homeostasis and transparency. Cytokine-mediated cellular communications are very complex and 
although the cell-cell cross talk is not fully understood, the communication that occurs is unlikely to be 
unidirectional [77]. The reciprocal interactions are fundamental to early development and extend into 
adulthood in maintaining organ function [127]. Although much work still needs to be done, it is 
apparent that cell-cell communication is fundamental in ensuring that the cells in the stromal layer 
maintain their keratocyte phenotype which is vital to the corneas development, homeostasis and 
response to environmental stimuli including injury and infection [128]. Specifically, the cellular 
communication aids in the restoration of activated keratocytes (fibroblasts) back to a quiescent 
keratocyte phenotype following injury, thus restoring tissue transparency which avoids excessive 
scarring that is detrimental to vision.  
Co-culturing of cells is becoming an increasingly popular method to create a full thickness cornea 
as it has the advantage of cell-cell interactions occurring, thus mimicking normal call behavior in a 
natural cornea. In co-culture systems 2 or more cell types are bought together within the same culture 
environment, enabling them to interact and communicate which can act as a very powerful in vitro tool 
allowing cellular interactions and cell function to be studied [129]. For example, when treating limbal 
stem cell deficiency (LSCD); a condition characterized by the loss of epithelial stem cells at the 
limbus, success is dependent upon the proliferative capacity of the transplanted epithelium over time. 
This in turn is determined by the origin and phenotype of the underlying stromal cells [48]. The 
influence of cellular interactions is of particular interest to tissue engineers because the tissue 
formation of one or all cell types can be regulated by simulating the natural physiology and 
differentiation of cells. Previous co-culture studies have displayed that a collagen gel matrix is 
essential for epithelial cell growth, and maintenance of structural differentiation [123] and that 
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additional stromal cell cultures can influence the differentiation of epithelial cultures and improve 
stratification of epithelial cells [111]. 
When developing co-culture models, it is important to balance the ability to observe, measure and 
manipulate cell behavior when constructing in vitro 3D environments [129]. For example, in vitro 
corneal tissue has been reconstructed previously [122,123] comprising of epithelial, stromal and 
endothelial cells in a 3D collagen matrix. Unfortunately the level of complexity involved deemed it 
unsuitable to accurately monitor and measure proliferation and differentiation in the component cells. 
Thus, often simplified models are required. These include the use of conditioned media [130], 
transwell cultures which utilize a semi-permeable membrane [65,131] and direct explant cultures.  
Hibino et al. [130] have utilized the use of epithelial conditioned media to investigate cell-seeded 
collagen gel contraction. Their results demonstrated that the addition of epithelial conditioned media 
accelerated construct contraction. However, it should be noted that the rabbit keratocytes used were of 
high passage number (P8) and were cultured in up to 12.5% FCS and that the epithelial cells were cultured 
in the presence of 15% FBS; thus the stromal cells were likely to be of a fibroblast/myofibroblast 
phenotype. Corneal wound healing can be stimulated by various exogenous cytokines [132] and many 
studies including the use of conditioned media, have been performed to help understand the 
underpinning pathways of intracellular signaling that control growth, differentiation and cell apoptosis. 
In doing this we could potentially identify specific intracellular targets for drug development that could 
effectively bypass dysfunctional cytokine receptor control for growth, differentiation and apoptosis [130]. 
Nakamura et al. [65] demonstrated in a co-culture system that injured epithelial cells secrete soluble 
factors able to cross a membrane impermeable to cells which stimulate corneal fibroblast proliferation, 
myodifferentiation and matrix contraction. In vivo epithelial-stromal interactions mediate fibrotic or a 
regenerative response, thus correct manipulation of culture conditions may facilitate the ability to 
control and initiate the cornea’s regenerative capacity on demand in in vitro cultures. Thus, it can be 
surmised that uninjured epithelial cells can likewise secrete soluble factors which can potentially 
influence fibroblasts to return to their pre-injury phenotype, i.e., a keratocyte.  
Nakazawa et al. [131] have performed co-culture studies by the use of insert dishes and companion 
plates to study epithelial-stromal and endothelial-stromal interactions. Stromal seeded collagen gels 
were cultured on the insert dish with either epithelial or endothelial cultures on the companion plate. 
The method is convenient in that it allows for the individual cultures to be easily separated and 
analysed in terms of growth and proteoglycan synthesis. Interestingly, they found that in comparison to 
mono-cultures, cell growth was not stimulated in any cell type in either epithelial-stromal or 
endothelial-stromal cultures. However, this is not consistent with the work of others [127,133,134]. 
The inconsistency was not determined in the study, although may have been due to the lack of 
successful adhesion of the epithelial and endothelial cells to the companion plates and/or the fact that 
the media was changed daily, which could reduce the stimulatory effect of the soluble cytokines 
released into the media. Additionally, the dispase treatment used to separate the cells from the tissue 
may have damaged the adhesion sites of the cells. However, it was noted in the previous studies that 
the proteoglycan content was significantly altered in the co-culture studies; stromal and epithelial cells 
stimulated proteoglycan synthesis by each other [127]. Analysis via proteoglycan radiolabelling 
demonstrated that epithelial and endothelial cultures had different effects on the stromal cultures, 
J. Funct. Biomater. 2012, 3            
 
 
675
suggesting that in vivo proteoglycan synthesis in a normal cornea is defined by a careful balance 
between the antipodal actions of the epithelial and endothelial layers [127]. 
Much of the existing literature regarding corneal co-culture is concerned with epithelial-stromal 
culture, with the emphasis being on the effect that the additional stromal cells (often fibroblastic in 
phenotype) will have on the epithelial culture. This may be due to the interest in treating limbal 
epithelial deficiencies and epithelial wounds. However, often corneal disease and injuries (such as 
chemical burns and Stevens-Johnson Syndrome [34]) penetrate deeper into the stromal layer so it is 
important to also consider the effects that epithelial cultures will have on the corresponding  
stromal culture.  
A greater understanding of stromal-epithelial-endothelial interactions and what mediates them by 
utilizing co-culture approaches offers great pharmacological potential in the regulation of corneal 
wound healing, with the potential to treat corneal diseases and injury whereby such interactions are 
vital [77]. As the different healing mechanisms, contributing factors and their potency become known, 
we are able to utilize this information in order to accelerate and enhance the wound healing 
process  [135]. However, despite the accomplishment of culturing epithelium, stromal cells and 
endothelium onto/in collagen based hydrogels there is still no tissue engineered corneal substitute 
suitable for clinical use. The production and culture of viable human endothelium is a prevalent factor, 
but the main problem still involves replication of the appropriate corneal stromal architecture [1].  
6.4.7. Growth Factors  
Growth factors and cytokines play a pivotal role in the wound healing process. In order to generate 
transparent corneal constructs via tissue engineering techniques a feasible strategy to control 
keratocyte activation and myofibroblast differentiation is to utilize the use of various growth factors. 
Many studies have been performed using this strategy, however they are often contradictory, and dose 
dependent or incomplete. For example, it has been shown that FGF may be used to stimulate epithelial 
coverage, but few studies have been performed to accurately verify this. FGF has also been shown to 
reduce the expression of α-SMA in 3D in vitro cultured keratocytes [68]. However, in 2D cultures FGF 
has caused fibroblastic differentiation [49]. The contradictory lack of stress fiber formation and change 
in matrix composition when in 3D cultures compared to 2D cultures suggests the FGF stimulation may 
be sensitive to the surrounding ECM. Additionally, discrepancies in FGF studies may be due to the use 
of non purified FGF from bovine brain or human placenta sources which will lead to controversy 
regarding the appropriate dosage [136]. Recombinant or purified FGF may be more appropriate to 
dose-response studies [136]. Discrepancies in the concentrations or combinations of growth factors 
used can affect the overall cellular response. 
There are 3 different isoforms of TGF-β in humans [40,41,69–71,73,75] and it becomes 
strategically obvious that we have to treat the TGF-β isomers differently. The in vivo affects of these 
growth factors have been mimicked in vitro via exogenous treatment with TGF-β1 and -β2 with the 
effects emphasized at higher cell densities [68]. The roles of each of the isoforms are distinct and differ 
from each other [71]. Although their exact roles still eludes us, it has been suggested that optimal 
treatment may rely upon selective inhibition of more than just one of the isoforms [72]. Inhibition of 
TGF-β1 and -β2 through the use of exogenous agents (such as Smads) and antibodies can reduce and 
J. Funct. Biomater. 2012, 3            
 
 
676
eliminate myofibroblast differentiation and fibrosis in vivo and in vitro [72,74]. TGF-β neutralizing 
antibody can prevent and block this action and has been used in previous collagen hydrogel co-culture 
studies to prevent hydrogel contraction caused by the release of soluble factors [65]. On the other 
hand, stimulation with TGF-β3 has been shown to yield corneal stromal models with non-fibroblastic 
characteristics with ECM properties that more closely mimic the native stromal ECM [71]. Hence, the 
use of TGF-β3 has been speculated for use as a therapeutic agent. TGF-β3 is thought to stimulate and 
activate different signaling molecules to TGF-β1 and TGF-β2 [71]. This results in a differential TGF-β 
function that inhibits type III collagen synthesis which is usually significantly upregulated and more 
abundant in wounded, fibrotic corneas [74]. Addition of TGF-β3 does not cause the upregulation  
of -α-SMA as occurs with the TGF-β1 and -β2 isoforms [71]. In agreement with these studies,  
Shah et al. [137] have also demonstrated that an increase in TGF-β3 production relative to TGF-β1 and 
TGF-β2 results in a scar-free phenotype.  
During TGF-β signal transduction a combination of proteins known as Smads are superficially 
initiated by TGF-β super family members [45]. Following TGF-β receptor binding, serine-threonine 
kinase receptors are activated which bind to receptor-activated Smads (R-Smads), Smad-2 and -3. 
These are then phosphorylated to form a complex with Smad-4. These complexes transfer into the 
nuclei whereby they organize transcription of the target gene [45]. Smad-7 acts by disrupting Smad-2 
and -3 activation via competitive binding to the TGF-β receptors, thus inhibiting TGF-β signal 
transduction. Additionally Smad-7, an inhibitory Smad can also prevent TGF-β signal transduction [45]. 
TGF-β2 has been established as the primary mediator of fibrosis and scarring. Blocking TGF-β2 using 
Smad-7 may reduce the keratocyte activation in response to injury thus preventing fibroblast and 
myofibroblast differentiation. It acts in the nucleus, altering the formation of TGF-β induced functional 
Smad-DNA complexes [45] and has a therapeutic potential for reducing excessive fibrosis and scarring.  
The effect of using PDGF is frequently associated with the use of serum in media which induces 
fibroblastic response. However serum contains a vast assortment of undefined factors as well as PDGF 
that may also contribute to the fibroblastic differentiation. When used in serum-free media, PDGF has 
been shown to facilitate the elongation and generation of dendritic procedures of stromal cells [17] and 
cause little matrix deformation. This allowed for keratocyte repopulation of the corneal stroma without 
disruption to the fibril architecture, thus reorganization of the surrounding matrix did not occur. PDGF 
encouraged more directional progression during migration without the production of stress fibers. The 
use of Rho kinase has had similar effects. Rho kinase belongs to a family of serine-theonine kinases, 
associated with regulation of shape and movement of cells. It controls the large traction forces 
generated by fibroblasts as they migrate. Inhibition of Rho kinase using Y-27632 inhibitor has been 
shown to alter the migration capability of stromal cells [17]. 
IGF has been used in vitro to stimulate keratocyte growth and proliferation and induces the elongation 
of the keratocyte dendritic processes [68] required for cell migration. Its inclusion in culture media can 
help to support corneal structure and may facilitate a regenerative wound healing phenotype [68]. Like 
EGF, KGF stimulates epithelial cell growth both in vivo and in vitro [40]. The exogenous in vivo 
addition of KGF to rabbit eyes following epithelial injury has shown to have growth promoting effects 
to epithelial cells [138]. It is thought to work by stimulating and increasing the mitotic activity of limbal 
epithelial stem cells in the regenerating cornea. Topical KGF treatment may have clinical potential in the 
treatment of epithelial disorders, in particular those requiring stem cell differentiation [69] as, unlike 
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many other growth factors, it does not affect cells of mesoderm origin and thus does not induce 
neurovascularisation of the cornea as a side effect [138].  
In vivo cytokines and growth factors are involved in complex feedback mechanisms whereby the 
activation of their receptor in a target cell can stimulate the production of additional growth factors and 
so on. This cascade affect promotes cross-talk to the original cell in a reciprocal epithelial-stromal 
interaction [46]. Thus when attempting to understand and manipulate the use of growth factors to 
control cell phenotype in tissue engineered constructs and/or a wound healing outcome (i.e., fibrosis or 
scarring) the use of single growth factors is not enough. We must first unpick and understand the 
intricate mechanisms and intricate combinations of growth factors will be needed to provoke the 
desired response. In order to determine an environment that stimulates organized keratocyte migration 
and generation a suitable model system is needed that will allow for stromal cells to be studied in their 
natural, uninjured state.  
6.5. Summary 
The design of any tissue replacement requires a comprehensive knowledge and understanding of the 
capacity of the native tissue [1]. There have been compelling advances in the development of synthetic 
corneal replacements and culture of human corneal cells onto and within supporting natural substrates. 
However, the gross results of these developments are poor and there are currently transplantable tissue 
engineered corneal equivalents to date [1,89]. There are currently only 2 clinically applicable synthetic 
cornea replacements (AlphaCorTM and the Boston Type-1 keratoprothesis [1]) and as of yet no viable 
tissue engineered corneas for treatment of end stage corneal diseases. Mimicking the complex 
organization of the corneal architecture is a current stumbling block. Two specific hurdles in particular 
need to be elucidated before appropriate tissue engineered corneas can be accomplished: 
(i) replacement or replication of the ultrastructure of the ECM; (ii) production of a dependable supply 
of untransformed proliferative corneal endothelial cells. Additionally lack of tensile strength to permit 
surgical manipulation and attachment of the corneal equivalent along with the correct formation of 
appropriate surface curvature [34] are problems that need addressing. Once these are solved storage 
and transport of the corneal equivalents will need to be reviewed.  
The capacity to successfully culture corneal stromal cells is progressing and the ability to determine 
differentiation state, contractile behavior and secretion of matrix components via manipulation of 
factors including but not limited to TGF-β and ascorbic acid derivatives are all encouraging. 
Commonly used reconstituted type I collagen gels are unlike the real stroma (with the exception of 
containing type I collagen and stromal cells) Controlling the assembly and/or remodeling of the 
collagen ECM is impediment as the principle functions of the cornea (strength, transparency 
refraction) are all directly connected to the nanoscale organization. The utilization of collagen films 
and nanoscale aligned structures in order to guide stromal cell migration and deposition of collagen 
and ECM is bringing researchers closer to achieving this goal. 
7. Conclusions 
The cornea is an excellent model for studying wound response with regards to cell phenotype due to 
the unique homogenicity of the cell types that reside in the defined cell layers and the remarkably 
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organized tissue architecture that if disrupted has immediate and obvious effects. Following injury or 
disease, the cornea is capable of restoring full function via a regenerative approach and one of the most 
demanding challenges in corneal biology is in the assistance of tissue repair via regeneration as 
opposed to fibrosis. The interaction between the corneal stroma and the adjacent epithelium is known 
to have a role in wound healing mechanisms although the exact mechanism is unknown. Derivations in 
its barrier function render it permeable to cytokines and growth factors which can facilitate an 
activated fibrotic response and scarring. Scar tissue alters the constituents of the original ground 
substance of the cornea including the proteoglycans, collagen filaments and various proteins via 
dynamic feedback mechanisms. The extent of damage or injury is known to have an effect on these 
mechanisms and may dictate whether the healing response is regenerative or fibrotic. Thus recognizing 
the diverse epidemiologies of common corneal injuries and diseases is of great significance to corneal 
research and medicine as it may aid in devising more appropriate treatments and preventative 
measures. Many of the existing treatments fail to cure the underlying cause, are not cost effective and 
can only alleviate or treat the secondary symptoms of disease. More knowledge of the underpinning 
mechanism that leads to scar formation and permanent opacities will aid in treatment.  
Corneal surgery techniques and procedures are widely used to improve the refractive properties of 
the cornea usually via an alteration to the corneal curvature. They are often criticized though for their 
unpredictability which results in over or under correction, astigmatism, ectasia and scarring. Further 
knowledge of wound healing following surgical procedures, management of post operative pain and 
more effective methods of controlling scar formation are continuous challenges. Appropriate models 
may aid in this challenge.  
Currently, the only truly successful treatment available for many corneal diseases is corneal 
transplant. However, the lack of donor tissue and relative high graft failure rates warrant the need for 
alternative procedures [18,89]. Tissue engineered corneas provide a promising solution in comparison 
to xenografts and keratoprotheses. Nevertheless, there is still no clinically available tissue engineered 
substitute available to date and tissue engineered corneas are currently limited to in vitro  
applications [93]. The production of a viable endothelial layer is a prevalent factor although replication 
of the stromal architecture and maintenance of stromal cell phenotype are still the biggest obstacles. 
Efforts have been made to mimic such architecture although still fail to meet the nanoscale 
arrangement. Concerted research efforts by multi-disciplinary research groups are ever adding to our 
knowledge of the complex systems required to restore and enhance vision in both in vivo and in vitro 
models. An accumulation of this knowledge will bring us closer to achieving this goal. 
8. Perspectives  
The control of scar tissue formation is undoubtedly of significant relevance from both clinical 
treatment of corneal diseases and corneal regeneration perspectives. The central challenges are the 
control of stromal cell phenotype and the organization of stromal ECM. Tissue engineered corneas 
could be super in vitro models allowing us to accumulate the knowledge of precise cytokine and 
growth factor mechanisms involved in fibrotic and regenerative healing via the addition of specific 
growth factors and chemical cues individually or in combination. Corneal research and tissue 
engineering techniques need to be tailored to fulfill the clinical pull and demand. Understanding the 
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wound healing mechanisms and what mediates them will determine and target specific exogenous 
factors that can be used to inhibit a fibrotic response thus aiding drug development and corneal disease 
treatment. The future direction of corneal tissue engineering is to further define the complex cell-cell 
and cell-matrix cross talk that occurs amongst the different cell types during the wound healing 
cascade. Defined 3D co-culture conditions and application of nanotechnology for stromal ECM 
reconstruction will allow us to build up more complex corneal models and echo in vivo scenario. Smart 
tissue engineering constructs provide a platform to delineate to impact of individual or combinatorial 
molecules. This transferrable knowledge will be beneficial for treating corneal disease and injury, in 
preventing or alleviating corneal scarring for clinical applications and encouraging corneal healing to 
adopt regenerative healing mechanisms as opposed to reparative fibrotic responses.  
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